**Nutrition for the aging brain: towards evidence for an optimal diet**

David Vauzoura, Maria Camprubi Roblesb, Sophie Kergoatc, Cristina Andres-Lacuevad, Diána Bánátie, Pascale Barberger-Gateauf, Gene L. Bowmang, Laura Caberlottoh, Robert Clarkei, Eef Hogervorstj, Amanda Kiliaank, Ugo Luccal, Claudine Manachm, Anne-Marie Minihanea, Ellen Siobhan Mitchellg, Robert Perneczkyn, Hugh Perryo, Anne-Marie Rousselp, Jeroen Schuermanse\*, John Sijbenq, Jeremy PE Spencerr, Sandrine Thurets, Ondine van de Restt, Maurits Vandewoudeu, Keith Wesnesv, Robert L Williamsw, Robin SB Williamsx, Maria Ramirezb

a University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK.

b Abbott Nutrition R&D, Abbott Laboratories, Camino de Purchil 68, 18004 Granada, Spain.

c Wrigley (Mars Inc.), 1132 W. Blackhawk Street, 60622 Chicago, IL, US.

d University of Barcelona, Av Joan XXIII s/n, 08028 Barcelona, Spain.

e International Life Sciences Institute, Europe (ILSI Europe), Av E. Mounnier 83, box 6, 1200 Brussels, Belgium.

f Univ. Bordeaux, Inserm, U897, F33076 Bordeaux cedex, France.

g Nestlé Institute of Health Sciences, EPFL Innovation Park, 1015 Laussanne, Switzerland.

h The Microsoft Research - University of Trento, Centre for Computational and Systems Biology (COSBI), Piazza Manifattura 1, 38068 Rovereto (TN) – Italy

I Oxford University, Richard Doll Building, Old Road Campus, Roosevelt Drive, OX3 7LF Oxford, UK.

j Loughborough University, Brockington Building, Asby Road, LE11 3TU Loughborough, UK.

k Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, Netherlands.

l IRCCS - Instituto di Richerche Farmacologiche Mario Negri, Via G. La Masa 19, 20156 Milan, Italy.

mINRA, UMR 1019, Human Nutrition Unit, CRNH Auvergne, 63000 Clermont-Ferrand, France.

n Imperial College London, South Kensington Campus, SW7 2AZ London, UK.

o University of Southampton, Tremona Road, SO16 6YD, Southampton, UK.

p Joseph Fourier University, Domaine de la Merci, 38706 La Tronche, France.

q Nutricia Research, Nutricia Advances Medical Nutrition, PO Box 80141, 3508TC, Utrecht, Netherlands.

r University of Reading, Whiteknights, PO Box 217, RG6 6AH Reading, Berkshire, UK.

s King’s College London, Institute of Psychiatry, Psychology and Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, 125 Coldharbour Lane, SE5 9NU London, UK.

t Wageningen University, PO Box 8129, 6700 EV Wageningen, Netherlands.

u University of Antwerp, Leopoldstraat 26, 2000 Antwerpen, Belgium.

v Wesnes Cognition Ltd, Little Paddock, Streatley on Thames, RG8 9RD, UK; Department of Psychology, Northumbria University, Newcastle, UK; Centre for Human Psychopharmacology, Swinburne University, Melbourne, Australia; Medicinal Plant Research Group, Newcastle University, UK.

w University of Bath, Claverton Down, BA2 7AY Bath, UK.

x Royal Holloway, University of London, Egham, TW20 0EX, Surrey, UK.

Running title: Nutrition for the aging brain

\*Correspondence address: Jeroen Schuermans. International Life Sciences Institute, Europe (ILSI Europe), Av E. Mounnier 83, box 6, 1200 Brussels, Belgium. Phone: +32 (0)2 775 91 35. E-mail address: jschuermans@ilsieurope.be

**Abstract**

Aging is a highly complex process marked by successive events which impair normal functioning of an organism over time and includes cognitive decline and many common chronic neurodegenerative diseases. So far, the majority of existing drug treatments for neurodegenerative disorders are unable to prevent the underlying degeneration of neurons. Consequently, there is a desire to develop alternative strategies, such as nutritional interventions. The present review is the most recent in a series produced by the International Life Sciences Institute Europe (ILSI Europe). It is co-authored by the speakers from a 2014 workshop led by the Nutrition and Mental Performance Task Force entitled ‘Nutrition for the aging brain: Towards evidence to an optimal diet’. The most recent scientific advances specific to how dietary, nutrients and non-nutrient may affect cognitive aging, is presented. In addition, several key points related to mechanisms contributing to brain aging, pathological conditions affecting brain function, and brain biomarkers are also discussed. Overall, growing preclinical and clinical research in healthy individuals or the earlier stages of cognitive decline has demonstrated the potential beneficial impact of nutrition on cognition in the elderly. However, findings are inconsistent and fragmented and more research is warranted to determine underlying mechanisms and to establish dose-response relationships for optimal brain maintenance in different population subgroups. Such approaches are likely to provide the evidence to develop research portfolios that will inform about new dietary recommendations on how to prevent cognitive decline.

**Keywords:** Cognition; preventive diet; cognitive decline; neuroprotection; neuroinflammation; cognitive aging; randomized controlled trial; epidemiology.

**Introduction**

The significant increase in average life expectancy is one of society’s great achievements which has been associated with a shift in the leading causes of illnesses from infectious to non-communicable diseases. It is well known that the percentage of populations categorized as elderly (e.g. 65 years and older) will increase dramatically in almost every country in the next few decades. By 2060, the elderly population will be expected to grow from 17.4% to nearly 30% worldwide [1]. At the same time, there is a wealth of disparate data related to how nutrients, non-nutrient food components and whole diets may impact on cognitive health and aging. Numerous epidemiological studies indicate that long-term intake of a Mediterranean diet (emphasizing amongst others fruits, vegetables, and olive oil) correlates with better cognition in aged populations [2-4]. Mechanistic investigations *in vitro* and in animal models have demonstrated that anti-inflammatory compounds in plants stimulate neurogenesis and protect neurons from noxious insults. However, such studies could not be replicated in humans [5] and treatments with ibuprofen, or foods, such as turmeric, although decrease pro-inflammation biomarkers only rarely show any pro-cognition effects, at least in intervention trials [6, 7]. Due to the lack of highly sensitive cognitive test batteries and control for individual differences, diets and nutrients are not proven to robustly alleviate cognitive decline over short periods.

In the past 10 years, high-calorie/low-dietary fibre diets and risk and incidence of diet-related diseases (i.e. type 2 Diabetes Mellitus (T2DM) or cardiovascular disease (CVD)) have been associated with age-related cognitive decline [8-11]. Available data on beneficial effects of several ingredients or nutrients (e.g. dietary fibre, low-glycaemic carbohydrates, resveratrol and docosahexaenoic acid (DHA)) suggest that their consumption may decrease glycaemic spikes or improve plasma cholesterol or triglycerides levels, thus having the potential to help prevent cognitive decline [12, 13].

Randomized placebo-controlled trials (RCTs) are the gold standard to confirm the effect of a nutritional intervention on cognitive decline, maintenance or improvement. However, such trials may be impossible to conduct for some nutrients, where subtle effects are predicted to add up over decades and may be significantly influenced by individual differences in the rate of cognitive decline.

Currently, there are no dietary recommendations or accepted health claims referring to age-related cognition on the foodstuffs marketed. It may be expedient to weigh evidence from pilot, cohort, case control and animal studies, and evaluate these together, rather than taking into account only RCTs. Some nutrients may exhibit stronger effects in conjunction with others, and thus, one aim of this review is to weigh effects of nutrients in isolation, such as DHA taken as fish oil supplements, versus combinations of particular bioactives such as found in the Mediterranean diet. Therefore, the main goal of the present review is to provide the most recent evidence from human observational and intervention trials along with key mechanistic studies in cell and animal models, on the current state of knowledge on nutrition and healthy brain aging.

**Normal and pathological decline in cognitive function**

Major aspects of human cognitive function are influenced by a variety of factors including genetics, lifestyle, nutrition, disease, trauma, medicines, as well as both normal and pathological aging. The group led by Salthouse [14] has compiled a convincing body of evidence demonstrating that notable age-related decline in cognitive function occurs in healthy individuals starting from the late 20s and continuing throughout the adult lifespan. Some headline conclusions from this research are that such decline occurs in all individuals, concern a wide range of major aspects of cognitive function (i.e. not simply memory) and are marked in nature (e.g. up to 2 standard deviations). Such findings have now been widely replicated [15, 16] and an important message is that the same aspects of cognition which decline with aging also decline (at a much greater rate) both in Mild Cognitive Impairment (MCI) and in the dementias [17]. Despite this compelling evidence, there is little regulatory support for the development of medicines to treat such declines. It is proposed that this time-based deterioration to crucial aspects of mental ability in healthy individuals should receive the same aggressive treatments as other age-related declines (such as eyesight deterioration). Nevertheless, there was a temporary surge of interest in this area over 25 years ago when the National Institute of Mental Health (NIMH) workgroup defined operational criteria for age-associated memory impairment [18]. Then, over the next few years a variety of drugs were evaluated to treat this condition with some limited success (e.g. phosphatidylserine) [19]. Criticism from some quarters that the pharmaceutical industry was creating a new condition simply to sell drugs to treat something which occurs in most individuals [20] led the industry to move away from this area and concentrate on pathological declines such as MCI, Alzheimer’s disease (AD) and other dementias [15]. In fact, during the last 10 years the news for novel drugs to treat MCI and AD has been overwhelmingly negative. No novel treatment has been approved for treating AD, despite a massive worldwide research effort which has been overshadowed by the failure of over a hundred putative treatments [21-23]. This has led the field to move its focus to prodromal and even preclinical stages of dementia, stimulated by diagnostic criteria designed in 2007 to capture earlier stages based on early episodic memory loss alongside with biomarker evidence of disease pathology [24]. These criteria have been further refined [25, 26] and the goal posts broadened considerably with operational research criteria for preclinical AD [27]. Preclinical AD is particularly relevant as the trials would involve cognitively healthy elderly population. Regulatory authorities have become proactive. In fact, in a recent publication authored by Food and Drug Administration (FDA) officials the point was made that in preclinical AD trials, where functional impairment would be difficult to assess, it could be feasible to approve a drug through the FDA’s accelerated approval pathway on the basis of assessment of cognitive function alone [28]. Therefore, a regulatory avenue has been opened in addition to new clinical criteria, and large trials in preclinical AD are already underway.

**Biomarkers of cognitive status**

AD is a slowly progressive neurodegenerative disorder with duration of several decades [29] showing 3 different phases; one preclinical and asymptomatic, a second one when cognitive performance starts to decline, and the last phase characterized by the typical memory-dominant dementia syndrome, which impairs everyday activities and patient autonomy [30]. In neuropsychiatric tradition, AD could only be diagnosed in a clinical setting if dementia was present, but a paradigm shift towards a more biologically defined AD diagnosis has been observed in recent years. The new National Institute on Aging-Alzheimer’s Association (NIA-AA) guidelines conceptualize AD as a progressive disorder including all possible stages from pre-symptomatic to severely demented [29, 31]. This way of thinking implies that tissue changes precede the onset of clinical signs by many years, and neuropathological lesions can be found in elderly individuals who presently do not have, and may not live long enough to ever suffer from cognitive impairment and associated disability [32].

During the past 30 years, a large body of evidence has been accumulated indicating that a cascade of events related to the faulty production, degradation and clearance of amyloid-β protein (Aβ) lie at the heart of AD pathogenesis. Upstream events within this cascade include the overproduction of the amyloid-β precursor protein (AβPP) caused by rare mutations in the AβPP, PSEN1 or PSEN2 genes, malfunctioning of Aβ-degrading proteases and impaired clearance as a result of ineffective active or passive transport mechanisms [29]. The imbalance between production and clearance results in excessive amounts of Aβ, which are believed to trigger a sequence of subsequent, i.e. downstream, pathological changes such as loss of synapses and neurons, impaired glucose utilisation, oxidative damage, brain metabolic reduction, tau hyperphosphorylation and associated neurofibrillary tangle formation, Aβ deposition in plaques and eventually neurotransmitter changes and widespread neurodegeneration. This complex cascade of pathological events continues throughout the course of AD, leading to an accumulation of structural and functional cerebral damages causing the typical clinical feature of disease [29, 33].

The hope for disease modification as well as technological advances in biomarker discovery fuel the search for biological indicators of the AD pathophysiological process, which can be used to identify neurodegeneration independently of its clinical manifestations [34]. Ideally, such a biomarker, alone or in combination with other markers, would distinguish between individuals with and without AD pathology. Furthermore, pathophysiological markers may also offer the added benefit of directly assessing response to treatment options that target core processes of AD pathogenesis. However, biomarker evidence of treatment efficacy should not replace clinical evidence of patient benefit.

Currently available AD biomarkers can generally be grouped into 2 categories. The first category comprises markers that indicate the type of pathology present, including cerebrospinal fluid (CSF) levels of Aβ1-42, total tau (tTau) and phosphorylated tau (pTau)181 [35]and positron emission tomography (PET) tracers of fibrillar amyloid such as flutemetamol, florbetapir, florbetaben and Pittsburgh Compound B [36]. The second category consists of markers that provide information on the topography of pathological changes, such as MRI and fluorodeoxyglucose PET [25]. Published evidence consistently shows that these biomarkers, alone or in combination with psychometric test results, offer an added value for the diagnosis of the early clinical stages of AD. Novel biomarkers that are more closely related to the core pathophysiological processes of AD are currently in development [37] such as soluble forms of APP, which can be measured in CSF [38] and blood [39].

**Metabolic and molecular mechanisms contributing to brain aging**

**Cardiometabolic risk factors**

The role of cardiometabolic health, including vascular stiffness and reactivity in cognitive health and decline are being increasingly recognized. In a 1-year longitudinal study in patients older than 80 years higher aortic stiffness was associated with more pronounced decline in cognitive function [40], and microvascular function was significantly impaired in dementia patients as compared to controls [41]. Although, the line between normal and pathological aging may not be well-defined, certain metabolic alterations such as obesity or T2DM may account for an increased risk of suffering age-related cognitive decline, especially in the elderly. The dramatic global increase in the incidence of obesity over the last 50 years is having a large effect on the incidence of many chronic diseases including T2DM and dementia. Indeed, more than half (52%) of the adult population in the 27 European Union (EU) member states are overweight (Body Mass Index; BMI= 25.0-29.9 kg/m2) or obese (BMI ≥ 30.0 kg/m2) [42] with an average EU obesity incidence of 17% in adults [42]. An excess of adipose tissue and its associated co-morbidities in middle-age, has emerged as a significant risk factor for age-related cognitive decline. A 27-year US cohort which consisted of overweight and obese individuals (aged 40-45 years) showed an odds-ratio (OR) (95% confidence interval (CI) of dementia of 1.35 (1.14-1.60) and 1.74 (1.34-2.26), respectively, relative to normal weight individuals [8]. Comparable effect sizes of 1.5-2.0 OR have been documented in more recent analyses, including a meta-analysis, which reported an attributed risk of 12% of total dementia and 21% of AD associated with obesity in a US population [9]. Indeed, including midlife obesity in forecast models typically results in a 10-20% higher prevalence of dementia [10, 11] than the doubling of prevalence predicted by 2030 based only on aging-related demographics [43].

For the metabolic syndrome (MetS) and T2DM comparable impacts on dementia risk have been reported to overweight and obese individuals, respectively. In a study which aimed to determine whether MetS was a risk factor for cognitive aging, a relative risk (95% CI) of 1.20 (1.02-1.41) of cognitive impairment was evident in MetS subjects as compared to controls [44]. In a meta-analysis of 19 studies, subjects with diabetes had a relative risk of any dementia of 1.51 (1.31-1.74), of AD of 1.46 (1.20-1.77), of vascular dementia of 2.48 (2.08-2.96) and of MCI of 1.21 (1.02-1.45) [45]. Interestingly, some results have demonstrated that diabetes increases the risk of AD independently of *APOE* genotype status, although subjects with T2DM and the *APOE ɛ4* allele (25% Caucasians), which is the most significant common genetic risk factor for AD, have the highest risk [45].

Deregulated glucose and insulin metabolism are core components of the obesity, T2DM and the MetS phenotype. Although some understanding exists regarding the role of glucose and insulin within the central nervous system (CNS), the physiological and molecular basis of the contribution of obesity and its comorbidities to cognitive decline, along with causality and independence of associations are poorly understood [46], but are likely to include: a) impaired vascular function and brain perfusion [40, 41, 47, 48], b) low grade inflammation, including altered adipose tissue production of adipokines [49, 50], c) poor glucose tolerance and utilization [51], and d) loss of insulin sensitivity independent of the impact on glucose metabolism [52-55]. In this context, AD is currently proposed as an “insulin resistant brain state” [56]. In addition, insulin in the CNS is largely derived from the periphery (pancreas) with some local insulin produced by the *dentate gyrus* (hippocampus) and olfactory system [57]. In neurons, insulin regulates energy metabolism, differentiation, growth, survival, synaptic plasticity and neurotransmission and promotes hippocampal long-term potentiation (LTP), learning and memory [52, 57-59]. Therefore, a loss of insulin sensitivity would be predicted to negatively impact on these metabolic processes.

**Anaemia**

The role of anaemia on cognition is still controversial and the potential mechanisms by which anaemia could impact on cognitive decline are still not understood [60]. The main hypothesis proposed, points to the role of the chronic low oxygenation of the aerobic cortical tissue, even more in the presence of compromised compensatory processes due to the neurodegenerative or vascular pathology underlying MCI [60]. Alternatively, anaemia has been suggested as a frequent complication of chronic kidney disease which leads to decreased erythropoietin levels that in turn may increase the risk of neurodegeneration [60].

The number of studies investigating the relationship between anaemia or haemoglobin concentration and dementia or cognitive decline has increased in recent years. However, the results of these studies are inconsistent [61]. Conflicting results have been found in studies investigating the association between anaemia or haemoglobin concentration and dementia or AD or vascular dementia mainly due to not appropriately adjusted confounding factors or inaccurate methodology [61]. Consequently, larger size, prospective, more representative and methodologically robust studies are needed to establish the possible effect of mild anemia on cognition in elderly persons.

**Oxidative stress**

The brain is a highly metabolically active tissue that relies on oxidative phosphorylation as a way for maintaining energy. The level of oxidative stress plays a pivotal role in brain functioning and growing evidence suggests a delicate balance between free radicals production and brain protection or damage [62]. A moderate oxy-radical production by the mitochondria, reported as physiological level of oxidative stress, is known to up regulate the mitochondrial biogenesis program and brain antioxidant capacity, and to act in brain protection. By contrast, accumulation of oxidative damages is a key mechanism of the aging process and a common feature of aging brain. That, together with age-related mitochondria decay, causes alterations of cellular architecture within the brain, and raises the fact that uncontrolled free radical production is a major contributor to the loss of neuronal homeostasis and neurodegenerative diseases development [63].

**Neuroinflammation**

It has been observed that in animal models of AD and Parkinson Disease, systemic inflammation generates an exacerbated immune response in the CNS through the local innate immune system. Then, the priming pattern triggered by activated microglia, can be influenced not only by the sequence of neurodegeneration, but also by the systemic inflammation or other secondary stimuli. Priming makes the microglia susceptible to a secondary inflammatory stimulus, which can then trigger an exaggerated inflammatory response [64]. Activated microglia has the capacity to synthesize a wide range of pro-inflammatory and anti-inflammatory cytokines and molecular mediators which contribute to the systemic inflammatory *milieu* and to the progression of neurodegenerative disease [65, 66]. During neurodegenerative events, neural damage leads to a loss or down regulation of neural ligands that bind to inhibitory receptors on the microglia, resulting in a reduced microglia inhibition. Priming of macrophages has been widely studied *in vitro* following the exposure to IFN-ɣ and lipopolysaccharide [67]. Low doses of lipopolysaccharides are sufficient to trigger microglia activation and sickness behaviour in both humans and non-human primates [68-70].

Nevertheless, other molecules expressed in the injured brain such as the colony-stimulating factor-1 (CSF-1) [71] and C-C motif chemokine 2 (CCL2) [72, 73] can also prime microglia. Activation of CSF-1 receptor (CSF-1R) by CSF-1 and IL-34 [74, 75] drives microglia proliferation [76], which is significantly important since the primed state and the increased number of microglia both contribute to the exaggerated response observed in the brain in neurodegenerative disorders.

In addition, mutations in CSF-1R also lead to important white matter damages associated with progressive dementia but the disease onset and severity strongly depend on the mutation [77]. The effects of the mutation on white matter region along with the fact that microglia remains more in white matter than in gray matter, suggest that microglia may have an important role in myelin or axonal homeostasis.

Aging, as the main risk factor for AD development, occurs with a chronic, low-grade systemic upregulation of the proinflammatory T helper type 1 response and a relative decline in the anti-inflammatory T helper type 2 response [78]. A study which examined brains samples from patients with mild or late-stage AD investigated the type of the inflammatory response (M1- or M2-like: CNS activated microglia corresponding to ‘cytotoxic’ and ‘repair’ subpopulations of macrophages in other organs) and tried to find serum markers that were associated with these 2 phenotypes [79]. Noticeably, the M1-like state was associated with increased levels of CCL3 and the M2-like state with increased serum levels of IL-1 receptor antagonists.

It is well known that in the aging population, an increasing number of individuals have more than one systemic disease [80], which indicates that systemic inflammation has a relevant importance as a risk factor for AD. The group of Perry et al. has demonstrated that systemic inflammation and acute infections are associated with an enhanced rate of cognitive decline [81] and increased symptoms of sickness in AD patients [82].

Therefore, according to all these data, the monitoring and prompt treatment of systemic disease, inflammation and infection may delay neurodegenerative disease progression and improve quality of life [64].

**AMPK signalling and autophagy**

Although, the precise neurobiological origin of dementia remains controversial, systems medicine approaches integrating recent advances in molecular technologies with computational methods are able to address this complexity and to identify key molecular hubs relevant for neurodegenerative dementia. These approaches, supported by the fast growing knowledge of human interactome, offer a platform to systematically explore not only the molecular complexity of a particular disease but also the molecular relationships among apparently distinct diseases. The group of Caberlotto et al. [83] applied these novel systems biology approaches not only to clarify the molecular basis of AD, but also to characterize the molecular alterations of the subgroup of neurodegenerative disorders with the shared core symptom of dementia. By convergent analysis of multi-dimensional datasets, their study on AD revealed a major role of metabolism and, predominantly, of AMP-activated kinase (AMPK) as a central dis-regulated process in AD. AMPK is a core signalling pathway in cellular homeostasis and crucial regulator of energy metabolism. Through the examination of neurodegenerative dementias, they integrated not only the current knowledge on the specific diseases, but also the molecular targets of drugs for the treatment of dementia. This study underlined once more the role of AMPK signalling and autophagy, a self-degradative process that is important for balancing sources of energy in response to nutrient stress, as the molecular basis of neurodegenerative dementia [84]. Similar results were obtained from the integrative analysis of AD and T2DM, two multifactorial diseases of aging with marked common pathophysiological features, which confirmed the autophagy pathway as the molecular mechanism altered in both diseases [85].

**Prevention of cognitive decline through nutritional and other lifestyle interventions**

Preclinical and clinical studies provide valuable data regarding the effect of particular dietary patterns and/or specific nutrients on cognitive function. For example, deleterious dietary habits (overfeeding, high caloric/low dietary fibre diet or consumption of low antioxidant nutrients) and sedentary lifestyle, or emotional stress, have been reported as key environmental factors for oxidative stress and brain disorders [86, 87]. Insulin resistance (IR) which is found in overweight, MetS, and T2DM individuals is one of the leading causes of oxidative stress. Given the negative effects of IR, inflammation and oxidative stress in brain, several dietary components, acting as antioxidant, anti-inflammatory and/or insulin action potentiating factors, could positively participate in a preventive nutritional strategy for healthy aging of brain. It is therefore necessary to increase research on the benefits of nutrition and healthy eating habits in order to identify the best dietary recommendations in human population. These will enable the prevention or delay of diseases and disability and increase quality of life in the elderly [88]. Among existing dietary patterns, the Mediterranean diet fits the notion of a healthy eating pattern [89]. A meta-analysis showed that greater adherence to a Mediterranean-style dietary pattern during older adulthood was associated with a lower risk of developing several different health outcomes such as CVD, neurodegenerative disorders, cancer and overall mortality [90]. In general, the Mediterranean diet is characterized by a high intake of vegetables, fruits, cereals, nuts and olive oil (as the principal source of added fat), a moderate intake of fish and alcohol (mostly wine), and a low intake of dairy products, red meat and meat products [91]. Higher adherence to a Mediterranean-style diet was associated with higher intakes of several antioxidant nutrients, and other food bioactives such as polyphenols, which are present in fruits, vegetables, cereals and beverages such as wine, coffee and tea.

**Specific nutrient levels and age-related cognitive decline**

Examination of biochemical indicators of diet in subject populations at high risk for dementia can serve to develop an evidence base for distinct nutritional requirements for the prevention of cognitive decline. In addition, comprehensive assessment of nutritional status beyond single or few nutrients can provide insight into the interactive features between nutrients that may be relevant to translational efforts. Thus, these “nutrient biomarker patterns” can be related to risk for pathological, structural and metabolic changes that precede cognitive decline and provide insight into mechanism.

One of the earliest structural changes in the brain that precedes cognitive decline is the accumulation of paraventricular and subcortical deep white matter hyperintensities (WMH). These WMH may indicate a breakdown of the blood-brain barrier via ischemic changes and demyelination of axons [92] and are a risk factor for cognitive decline. The CSF/plasma ratio of blood derived albumin is another indicator of BBB function. Here an increase in the CSF/plasma albumin ratio indicates BBB breakdown [93]. The BBB impairment is prevalent in about 25% of autopsy confirmed AD cases and is associated with more rapid decline over time. Specific nutrient concentrations in the CSF appear to be influenced by BBB integrity and this loss of CNS concentration is associated with worse prognosis in AD cases [94]. Another study has demonstrated that BBB function is modifiable through vitamin therapies [95]. Thus maintaining BBB health may be one target for nutritional therapies aimed at maintaining cognitive function. This area and underlying changes at the BBB that influence transport and concentration of nutrients in the brain remain an open area for research.

One report applied a data-driven approach to derive nutrient biomarker patterns (NBPs) in the Oregon Brain Aging Study. The study included 104 subjects with a mean age of 87 years and free of dementia at baseline. Eight distinct NBPs were identified and examined in relation to domain specific cognitive function and MRI measures of brain aging [96]. The results were remarkable in the sense that it appeared that some NBPs were associated with global cognition and others mapped more to certain cognitive faculties only. This would suggest that certain nutrient combinations operate on general mechanisms in the brain while others are more discrete. For example, two NBPs were associated with more favourable cognitive and MRI measures: one vitamin profile (high plasma B vitamins, antioxidants C, and E and vitamins D) and another high in plasma ω-3 fatty acids. The vitamin profile explained a significant portion of variance in global cognitive function and particularly, attention, visuospatial and executive functions. It was also associated with less total brain atrophy, a phenomenon that can be driven by Alzheimer’s type pathology. The ω-3 pattern appeared more important to vascular aspects (WMH volume and executive functions known to be sensitive to WMH accumulation). A third pattern characterized by high trans-fat was associated with less favourable cognitive functions across several domains and more total brain atrophy. Memory function was better in those with higher plasma lutein and HDL cholesterol [96]. The NBPs altogether explained 17% of the total variation in global cognitive function and 37% of total variation in total brain volume. These data suggest that biochemical indicators of diet capture magnitudes of effect well beyond what we are accustomed to observing in nutrition research. One explanation is that the NBP analysis appreciates “synergistic” features, and another is that misclassification bias of nutritional exposure is reduced in comparison to more conventional methods subject measures of diet in older adults. In a longitudinal study of older adults at risk for dementia and followed over 4 years, plasma levels of the two long chain polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA) and DHA were associated with less executive function decline and that relationship appeared to be mediated by WMH burden [97]. These studies suggest that NBP analysis is a fruitful strategy for studying nutrition, metabolism and dementia. What and how nutrients influence the neurobiology that contributes to age-related cognitive decline warrants much more research. Combining human induced pluripotent stem cells (iPS) cells biology, molecular and nutritional neuroepidemiology and clinical trials is a way forward.

**Nutritional assessment for disease prevention**

The purpose of nutritional assessment is to well-characterize the dietary patterns of individuals, and to assess their exposure to nutrients and the hundreds of non-nutrients provided by the diet, for example phytochemicals, food additives, and food contaminants. Then, this information can provide scientific evidence for the role of dietary factors on human health and well-being. Other purposes of nutritional assessment are to identify population groups who do not have an adequate nutrition for disease prevention and to develop nutrition programs for at risk populations in order to monitor their impact. Nutritional assessment is still a huge challenge, due to the extraordinary heterogeneity and variability of food choices, and our limited knowledge of the composition of foods beyond the ~60 essential nutrients. Ideal methods of nutritional assessment should be accurate, sensitive and applicable to many populations. Currently, available methods fall into 4 categories: 1) anthropometric methods, 2) clinical examination, 3) questionnaires, and 4) biomarkers. Anthropometric methods such as BMI measurement have been considered as indicators of the adequacy of energy intake, but the correlation with diet quality is very questionable. Clinical examination has been used to diagnose severe vitamin or mineral deficiencies. However, this method is not appropriate for mild deficiencies. Today, dietary assessment is often conducted using Food Frequency Questionnaires (FFQs), where subjects must remember their intake of 10 to 300 food items over the previous year. Multiple 24 h recalls and food records are more precise but more expensive and therefore, other new technologies have been developed. Now, web-based questionnaires are applied in large cohort studies, as in the French NutriNet-Santé cohort which includes over 200,000 subjects [98]. Smart phone applications also seem promising. Nevertheless, even with more technology, questionnaires have inherent limitations due to self-reporting [88-90] and are susceptible to recall bias. Even if statistical techniques have been developed to correct measurement errors, questionnaires, especially FFQs, are suspected to markedly attenuate associations existing between dietary factors and health outcomes [91]. The last approach for nutritional assessment is the use of biomarkers, which are quantified through targeted analyses of biofluids or tissues [99, 100]. Biomarkers are independent of all the errors associated with questionnaires. Today, only a limited number of validated biomarkers of food intake have been use in epidemiology [99, 100], for example plasma vitamin C or carotenoids for fruit and vegetable intake, alkylresorcinols for whole grains, and urine methyl-histidine for meat. Some polyphenols have also been occasionally used as biomarkers of intake for their main dietary source [101], for example resveratrol for red wine or hesperetin for orange [102]. These biomarkers have been discovered using a hypothesis-driven approach which means that a specific compound of the food was previously known, its bioavailability was documented and then a reliable method of analysis could be developed. However, validated markers discovered with this approach do not cover the large diversity of food in the human diet, and many new biomarkers are still needed.

In the last decade, metabolomics has emerged as a data-driven approach for biomarker discovery. The concept of the food metabolome has been defined [103] which represents all the metabolites present in human tissues and biofluids that directly derive from the digestion and metabolism of food chemicals. The food metabolome is affected by both, the dietary habits and the metabolic capacity of individuals.

The group of Manach conducted a medium-term controlled intervention study to find biomarkers of citrus fruits intake [104] where 12 volunteers consumed 500 mL/day of orange juice or control drink for one month, in a cross-over design. The urine metabolomes analysed by non-targeted high resolution mass spectrometry were compared at the end of the experimental period. Some expected candidates biomarkers of orange juice intake were identified such as the glucuronides of the citrus flavanones, hesperetin and naringenin but new candidates were also found, including some terpene metabolites as well as proline betaine, which seemed even more sensitive than the flavanone metabolites [104]. Proline betaine has been validated in independent studies, quantified in a range of foods and was found almost exclusively in citrus fruits [105]. This case-study example demonstrates that metabolomics is an efficient approach to discover new reliable biomarkers of food intake in a data-driven approach.

In total, about 145 candidate biomarkers have been proposed for about 20 foods through these food metabolome studies, and interestingly about 75% were phytochemical metabolites [105]. These candidate metabolites must be validated as it has been done for proline betaine.

Since interventional studies for all the foods of the human diet are not feasible, the use of cohort samples to identify candidate intake biomarkers for a range of foods at the same time has been performed. The Phenotyping using Metabolomics for Nutritional Epidemiology (PhenoMeNEp) project aimed to develop a new innovative and integrative approach, based on mass spectrometry metabolomics, to characterize dietary intake and nutritional status of populations [106]. This project used the SU.VI.MAX2 cohort which is a well-characterized cohort of French adults. Importantly, they identified the strongest discriminant of coffee intake as Atractyligenine glucuronide, a phase II metabolite of a diterpene, which contributes to the bitter taste of roasted coffee and which has never been reported in significant amounts in any other food sources. Two others strong discriminants were alkaloids, the diketopiperazine cyclo (isoleucyl-prolyl) and trigonelline [106]. The three biomarkers were classified as excellent biomarkers when their performance was assessed using receiver-operating characteristic (ROC) curves test. Certainly, metabolomics-derived coffee biomarkers will be used in the coming years, in particular to study the impact of coffee on cognition.

The group of Manach has also developed a new database named PhytoHub (www.phytohub.eu) to facilitate the identification of phytochemical metabolites in the metabolomic profiles that will include all phytochemicals commonly ingested within the human diet, which represent about 1,000 compounds.

Therefore, profiling of urine or plasma metabolomes in interventions or cohorts studies is efficient to discover new candidate biomarkers of food intake (data-driven approach). Beyond biomarker discovery, food metabolome profiling covering a wide range of blood bioactives and biomarkers of intake in biofluids may become a new method for nutritional assessment.

**Micronutrients**

As reported by numerous studies in animals and humans, essential antioxidant trace elements such as Zinc (Zn), Selenium (Se)) and /or insulin sensitizers (Chromium (Cr), Zn) are deeply implicated in brain protection. Selenoproteins, i.e. Selenoprotein P and Glutathione peroxidase, protect brain cells against oxidative stress. A low Se status increases the risk of cognitive decline. The greater is the decrease in plasma Se, the higher is the probability of cognitive decline as indicated in the study of Akbaraly et al. [107]. A potential preventive relevance for an optimal Se status can be therefore speculated to maintain a healthy brain [63]. However, there is an absence of consistent clinical evidence regarding whether Se supplementation is beneficial for the treatment of AD [108].

Zn also acts positively on brain health by improving insulin sensitivity and reducing inflammation and oxidative stress. However, so far no benefits on aging brain are reported after Zn supplementation in humans and even a potential neurotoxic effect of Zn accumulation has been observed in AD patients [109].

Cr deficiency has resulted in insulin resistance (IR) and increased oxidative stress [110]. Indeed, in insulin resistant states (T2DM and MetS), increased Cr intakes are associated with improved cognitive functions [111].

**Polyphenols and polyphenol-rich diets**

A number of studies have observed protective associations between dietary polyphenols and the prevention of age-related chronic diseases such as CVD, diabetes, cancers, osteoporosis and neurodegenerative diseases [99-101]. The strongest evidence of health-protective properties is for CVDs [102, 103, 112]. However, the well-known biases and measurement errors of dietary assessment tools make the precision and accuracy of dietary intake estimations difficult, and therefore, the associations observed between polyphenols and health are compromised. As a result, it is still challenging to develop personalized diet-related recommendations for dietary polyphenol intake, and further research on the identification and validation of new nutritional biomarkers is warranted [113].

In the epidemiologic InCHIANTI study (Invecchiare in CHIANTI, aging in the Chianti area), the group of Andres-Lacueva investigated the associations between total urinary polyphenols, as biomarkers of total dietary polyphenols [114], and all-cause mortality over a 12-year period among older adult participants [115]. Recently, they also investigated the associations between total polyphenols and cognitive decline over a 3-year follow-up in older participants free of dementia at baseline [116]. In these studies, they observed that participants who consumed a diet rich in polyphenols (>600 mg/d) reduced the risk of all-cause mortality and the risk of cognitive decline in global cognitive function (using the mini-mental state examination), and in attention (using the Trail Making Test A), by 30%, 47% and 48%, respectively. By contrast, they did not reduce the risk of decline on executive function measured with the Trail Making Test B, as compared to those who consumed diets low in polyphenols (<500 mg/d). However, no association was observed between total urinary resveratrol metabolites, a biomarker of red wine consumption, and all-cause mortality [116].

In addition, research on aging effects has revealed several signalling pathways which have been experimentally demonstrated to be involved in the regulation of the aging process [117]. The central effects of these polyphenols, at the transcriptomic level confirmed the involvement of specific molecular component of the AMPK-autophagy systems also in neuronal and glial cells (unpublished data). The modulation of AMPK and autophagy could potentially prevent not only neurodegeneration, but also, in more general terms, it could promote healthy cognitive aging.

Cinnamon polyphenols also deserve a special attention since they have been reported to reverse *in vitro* Tau protein aggregation and break up Tau filaments [118]. Interestingly, cinnamon added to the diet also counteracts the increase of amyloid precursor protein (APP) and Tau protein induced by a high fat/high fructose diet in the rat brain [119].

Polyphenols intake is associated with consumption of fruits such as grapes, apples, pears, cherries and various berries containing between 200 and 300 mg of polyphenols per 100 g of fresh weight [120]. Moreover, a cup of tea or a large cup of coffee contains around 100 mg of polyphenols. Red wine, chocolate, legumes and nuts also contribute to the polyphenol intake. Recent development in analytical techniques and in metabolomics should allow the measurement of large sets of polyphenol metabolites as biomarkers of usual dietary polyphenol intake [120]. This will be essential if we are able, finally, to make dietary recommendations regarding polyphenols for improving the autonomy and quality of life in older people.

**Flavonoids**

Amongst polyphenols, the flavonoid subclass has been extensively studied. Given the wealth of available data for these phytochemicals, we decided to present those as a separate paragraph. Flavonoids, found in a variety of fruits, vegetables and beverages, have been recognized as promising agents capable of influencing different aspects of synaptic plasticity resulting in improvements in memory and learning in both animals and humans [121-123].

Accumulating evidence suggests that certain dietary flavonoids might delay the onset and/or slow the progression of AD [121], but the precise identity of the bioactive form(s) involved is unknown and critical information about bioavailability and metabolism has hindered progress in the field. Despite significant advances in our understanding of the biology of flavonoids over the past 15 years, they are still mistakenly regarded by many as acting simply as antioxidants. Yet, flavonoids are much more likely to combat neuronal dysfunction and toxicity by recruiting anti-apoptotic pro-survival signalling pathways, increasing antioxidant gene expression, and reducing Aβ pathology [55, 124]. There is, however, a lack of consensus as to the precise identities of the flavonoids capable of exerting these effects, partly because flavonoids have notoriously poor bioavailability and are extensively metabolised *in vivo,* but also because most *in vitro* studies use concentrations that are at least 100 fold higher than those found following dietary administration. The group of Williams has started to address some of these limitations by adopting unbiased *in vitro* screening strategies using flavonoids at concentrations that are potentially achievable in humans to mimic more closely what occurs *in vivo* as a first step towards identifying possible dietary interventions for AD [125]. Using an APP-GAL4 gene reporter assay in primary rodent neurones to screen modulators of APP processing they identified a number of flavonoids that potently inhibit βγ-secretase activity. Most notably, the flavanols (−)-epicatechin (EC) and epigallocatechin reduced βγ-secretase activity and Aβ production at nanomolar concentrations and reductions in Aβ pathology were also observed following oral administration of EC to APP-PS1 mutant mice.

Since EC is readily absorbed and circulates primarily as glucuronidated, sulfated, and O-methylated forms in human plasma, the observed bioactivity is most likely to reside in an EC metabolite. Therefore, Williams’ hypothesis was that dietary EC, acting as a *prodrug*, or alternatively a synthetic EC analogue based on a metabolite, had the potential to be developed into a prophylactic dietary supplement for AD. The molecular mechanism underlying this reduction in Aβ production both in wild-type neurons and in a transgenic model of AD is not clear but Williams et al. presented evidence suggesting that EC inhibits the β-site amyloid precursor protein cleaving enzyme 1 (BACE1) [125].

A large body of evidence has also emerged from human intervention studies demonstrating that the consumption of flavonoid-rich foods is associated with cognitive benefits (for a review see [121, 126]). The mechanisms by which flavonoids exert these actions on cognitive performance are being elaborated, with evidence suggesting that they may modulate the activation status of neuronal receptors, signalling proteins and gene expression [127-129]. Although whether these effects are mediated directly (i.e. within the brain) or from the periphery is currently unknown.

There is considerable evidence suggesting that neuronal activity during cognitive performance is tightly coupled to increases in regional blood flow, a process known as cerebrovascular coupling [130]. Such processes are primarily mediated by nitric oxide (NO) generated by the activation of both endothelial nitric oxide synthase (eNOS in endothelium) and neuronal nitric oxide synthase (nNOS in neurons) [131] (Fig. 2). In particular, NO derived from eNOS activation contributes to cerebral arterial dilatation, by migrating to vascular smooth cells and increasing blood flow at the blood-brain interface [132]. Furthermore, there is increasing evidence suggesting that the cerebrovascular response is also mediated by NO liberated from nNOS-containing neurons adjacent to intra-cerebral arterioles and capillaries [133].

There is substantial evidence which supports the beneficial effects of flavonoids, in particular flavanols [133, 134] and anthocyanins [135] on peripheral vascular function and blood flow (measured using flow mediated dilatation). These effects are mediated by the actions of absorbed flavonoid metabolites on NO bioavailability, via their potential to activate eNOS [133] and/or inhibit NADPH oxidase activity [135]. Such improvements in vascular function occur acutely e.g. flavanols (cocoa, tea; 1-3h) [133] and anthocyanins (blueberry; 1-2h and 5h+) [135], are in the same timeframe and show cognitive improvements using similar interventions type. Furthermore, flavonoid-induced improvements in spatial memory in animal models [127, 129] share similarities with those of exercise-induced alterations in synaptic plasticity in the brain [136, 137], as both involve the activation of the serine/threonine kinase Akt, also known as protein kinase B (PKB) (Akt/PKB), and the increased expression of brain-derived neurotrophic factor (BDNF) [138]. Indeed, Akt/PKB activates both eNOS and nNOS, via increases in intracellular Ca2+ levels in endothelial and neuronal cells, respectively [139, 140] and thus, that may represent a common path by which flavonoids and exercise facilitate cognitive improvements. The central role that NO plays in flavonoid-induced improvements in human cognition and cerebral blood flow has been explored by the use of NOS inhibitors, which block the conversion of L-arginine to L-citrulline and inhibit NO production [141]. Future studies should utilize L-arginine analogues such as nitro-L-arginine methyl ester, nitro-L-arginine, and L-*N* G-mono-methyl-arginine (L-NMMA) to help provide information on the role of NO and blood flow in mediating cognitive activity of polyphenols. Use of L-NMMA in humans has been shown to result in a fall in cerebral blood flow [142] without altering basal metabolic activity [143]. The use of NOS inhibitors *in vivo* has the potential to assess the contribution that NO plays in mediating increases in cerebral blood flow and hyperemic responses to cognitive activity in response to flavonoid intervention. Applying such an approach to polyphenol clinical trials will provide a clearer mechanistic understanding of how flavonoid intake acutely mediates cognition and how such transient blood flow alterations may underpin longer-term improvements in humans.

Recent datasets indicate that high flavanol intake (495 mg) is associated with improvements in human executive function and episodic memory at 2 h post-consumption, compared to a low flavanol control (23 mg) [144]. Similar data following anthocyanin intake (755 mg; delivered and controlled as blueberry) indicate that cognitive improvements are manifested at 5 h post intake reaching significance already at 1 h [144]. The time-course of these cognitive effects, along with Spencer’s recent peripheral vascular function/blood flow data, using flow-mediated dilatation (FMD) [135] suggested that the modulation of peripheral blood flow and cerebrovascular blood perfusion by flavanol-rich foods may mediate acute improvements in cognition. In support of this hypothesis, recent pilot data indicate that flavanol intake (495 mg) is capable of increasing cerebral blood perfusion within select regions of the brain, as measured by arterial spin labelling [144] in a timeframe consistent with both peripheral vascular and cognitive test performance. Further, a memory testing procedure known as pattern separation has recently been identified which has the potential to demonstrate therapeutic response in men to compounds which promote hippocampal neurogenesis [145, 146]. A paper has just appeared demonstrating that one of such tests was able to identify positive effects of a high-flavanol cocoa preparation in elderly healthy volunteers [147]. In this study, improved cognitive function with the cocoa preparation was accompanied by functional magnetic resonance imaging (fMRI) evidence of enhanced activity in the *dentate gyrus* which is the hippocampal site responsible for neurogenesis. However, to date, no cause-effect relationship has been investigated between flavonoid intake, vascular function and cognitive performance. In addition, very little is known about the longer-term effects of flavonoids on cognitive function in humans, or whether such effects may be sustained in the absence of intake, despite there has been a wealth of animal data in support of potential longer term efficacy [127-129, 148].

Despite clear evidence regarding the acute vascular effects of flavonoids shown in humans [126] and medium-term changes in synaptic plasticity markers demonstrated in animal studies [138], the basic mechanisms of action of flavonoids in humans remains unclear, due to a lack of precise causative/mechanistic data. Future work should strive to determine the mechanistic basis of flavonoids-induced improvements in cognitive function by investigating the degree to which peripheral- and cerebral blood flow induced by flavonoids metabolites plays in determining improvements in human cognitive performance, in particular attention and episodic memory.

**Vitamins**

Among vitamins, high dietary intakes of tocopherols are associated with a reduced AD or dementia incidence [149]. However, interventional studies using Vitamin E supplementation failed to report positive effects on the risk of AD [150]. For vitamin C, although there has been inconsistency among observational studies relating dietary intake of ascorbic acid to improved cognition, some results have favoured an important role for ascorbic acid in cognitive health. Therefore, further research focused on investigating the specific role of ascorbic acid in AD with special attention to the study design and methodologies, which represent an important study limitation, has been suggested to provide more conclusive data [151].

The mechanisms that support the relation between vitamins B and the brain are mostly related to homocysteine (Hcy) metabolism, a marker of vitamin B insufficiency. Hcy is catabolized through a remethylation cycle mediated by folate and vitamin B12, which provides methyl-group for several metabolic steps [152]. Clinical evidence has demonstrated a correlation between elevated plasma Hcy and the occurrence of AD and thus, hyperhomocysteinemia has been suggested as an important risk factor of AD [153, 154]. Observational studies have reported that people with high blood concentrations of Hcy have elevated risk for vascular disease [155] and AD [156]. These studies prompted randomized trials to assess whether vitamins B positively impacted on cognition, but their results have been mixed. In one of the most recent systematic reviews, 35 cohort studies with a total number of 14,235 individuals were identified [157]. Twenty-one studies were of good quality of which only 7 showed a beneficial association. This association was more consistent in studies that included the newer and more specific markers of vitamin B12 status such as methylmalonic acid (MMA) and holotranscobalamin (holoTC). The most recent Alzheimer’s Disease International (ADI) report on nutrition and dementia included 4 additional studies that all showed a beneficial association of a higher vitamin B status with less cognitive decline [158]. Even after including those more recent studies still the majority of observational studies did not show a beneficial association. A meta-analysis was performed on RCTs performed in individuals with or without cognitive impairment [159]. Nineteen RCTs were included and the overall conclusion was that no effect of vitamin B supplementation was observed on cognition. Similar findings were reported in an earlier Cochrane review [160], which concluded that 4 RCTs provided no evidence for improvement in people with cognitive impairment or dementia when treated with folic acid with or without vitamin B12 or B6. However, a later Cochrane update [161], which included 8 studies concluded that there was someeffect. For instance, a better response to cholinesterase treatment with vitamins B was observed in some studies including both people with AD and without dementia.

After these reviews some additional RCT results were published [162-164] of which 2 RCTs showed an effect. Several observational studies have included brain MRI and all showed at least some beneficial associations [165-169].

Some other conflicting results have been released by the Folate after Coronary Intervention Trial (FACIT) (n=800) which reported that folic acid had a significant effect on memory [170]. This study showed that people who were treated with folic acid and had high levels of Hcy (which is a risk factor for dementia and heart disease) had better cognitive function over a 2-3 year period than those who were not treated.

One recent RCT (VITACOG trial) including 168 MCI patients has been performed that included brain MRI as an outcome measure and showed that after 24 months of vitamin B supplementation patients showed a 30% slower rate of brain atrophy [167]. Additionally, in the same study it was demonstrated that vitamin B supplementation was able to slow the cognitive and clinical decline in people with MCI, in particular in those with elevated Hcy levels [171]. Despite this, reliable evidence requires large trials, avoidance of bias and sub-group analysis and meta-analyses of such trials. A recent meta-analysis by Clarke et al. [172] included all vitamin B trials assessing effects on cognitive function. It assessed the effects of vitamins B on individual domains of cognitive function, global cognitive function and cognitive aging. Dietary supplementation with vitamins B to lower Hcy levels had no significant effect on individual domains, global cognitive function or cognitive aging. Overall, it was shown that vitamins B had no beneficial effect on either cognitive aging [172] or vascular disease [173].

Another vitamin that has been widely investigated is vitamin D. Currently a large proportion of populations are vitamin D deficient, and in particular the elderly [174]. Some vitamin D receptors are located in the brain and many mechanisms that may support its role in the brain have been identified [175]. Regarding observational evidence, Balion et al. [176] identified 37 studies that could be included in his meta-analysis. There was a large heterogeneity, in particular in different cognitive tests that were used as an outcome measure. Results based on 8 studies using the Mini-Mental State Examination (MMSE) showed that participants with 25-hydroxyvitamin D (25(OH)D) concentrations >50 nmol/L had a higher MMSE score than those with concentrations <50 nmol/L.

**ω-3 PUFAs**

Long-chain ω-3 PUFAs, EPA and DHA have been associated with decreased brain inflammation and preservation of the integrity and function of neuronal membranes [177]. For example, DHA which is a key component of phospholipid cell membranes, may APP, thereby reducing formation and increasing clearance of β-amyloid, the main component of AD plaques [158].

Observational evidence has been focused on the association between fish long-chain ω-3 PUFA intake or ω-3 PUFA status and cognitive functioning, cognitive decline or dementia. More than 30 studies have been performed and the vast majority of studies have showed beneficial associations [178]. In the first Cochrane review on ω-3 PUFA trials that was published in 2006, no single RCT could be included [179]. That review was updated in 2012 and at that time the first RCTs in non-demented elderly and with a study duration of at least 6 months were published. In total, 3 RCTs were included with a total of 3,536 participants. The conclusion was that ω-3 PUFA supplementation had no effect on cognitive functioning [180]. In the same year Mazereeuw et al. [181] performed a meta-analysis and included cognitively impaired and demented individuals as well. They included 10 RCTs and did not observe an overall benefit for immediate recall after ω-3 PUFA supplementation in healthy or demented elderly. However, they found an effect on the specific cognitive domains for immediate recall, attention and processing speed in cognitively impaired non-demented individuals.

The research field is currently advancing by not only the inclusion of batteries of cognitive tests as an outcome measure, but also including MRI techniques. Several observational studies including brain MRI have been performed and all have showed at least some beneficial associations [182-187]. Also, one RCT has been performed in 65 healthy elderly and with a study duration of 26 weeks [188]. In this study beneficial effects were found on executive functioning, on the MRI measures of gray matter atrophy, and on white matter microstructural integrity.

**Calorie restriction**

Diet including total intake, frequency, and content has emerged as an important environmental factor that can impact brain plasticity, including adult hippocampal neurogenesis (AHN) [5, 189]. The level of AHN decreases with age and has been linked directly to cognition and mood [190]. In rodents, an increase of neurogenesis in the hippocampus is associated with improved learning/memory abilities, whereas a decrease is associated with symptoms of depression [191, 192]. Therefore, modulation of AHN by diet emerges as a potential mechanism by which nutrition impacts on mental health [193]. Synapse formation is a key site in the initiation of the neurodegenerative process occurring during AD pathology, and then, calorie restriction (CR) may have significant effects on the disease pathology via modulation of AHN and synaptic plasticity [194]. Wu et al. [195] found that CR (30% for 4 months) in the transgenic mouse model of AD significantly attenuated ventricle enlargement, hippocampal atrophy, and caspase-3- activation. For example, the effect of CR, limiting the intake compared to baseline unrestricted or *ad libitum* consumption, together with maintained levels of vitamin, mineral, or other essential biomolecules has appeared to increase AHN. Furthermore, CR seems to improve the resilience of synapses to metabolic and oxidative damage and modulates the structure and functional status of synapses [86]. Moreover, CR has demonstrated to induce the differential expression of genes of which 25% are involved in synaptic plasticity [196]. Mice have showed improved working memory after long-term CR [197, 198]. An increase in the expression of N-methyl-D-aspartate (NMDA) receptors, essential for LTP and synaptic plasticity, has been found in the hippocampus of 60% CR obese rats as compared to age-matched *ad libitum* fed animals [199]. Taken together, while still further research is warranted to elucidate the mechanisms by which some dietary factors induce brain plasticity, animal and supported epidemiological studies have demonstrated that multiple dietary regimens and components increase the levels of AHN, enhance brain plasticity and promote synaptic function in the context of aging.

**Ketogenic diets**

Very-low-carbohydrate ketogenic diets (VLCKD) have been used for many decades especially after the 1970s when they became popular for weight loss [200]. But it was in the early 1920s when the importance of the use of these diets became relevant from the clinical point of view and were successfully used to treat many pathological conditions such as epilepsy [201], diabetes [202], CVD factors [203] and neurological diseases [204]. The review by Paoli et al. [205] considers possible mechanisms for the therapeutic actions of the ketogenic diet (KD) on weight reduction and different diseases such as CVD and diabetes. Although, the exact mechanisms of action of the KD are still poorly understood recently reports have suggested that ketone bodies (KB) act as neuroprotective agents by raising ATP levels, diminishing the production of reactive oxygen species in neurological tissues and enhancing the regulation of synaptic function though mitochondrial biogenesis [206]. Moreover, the stimulation of PUFAs synthesis by a KD has been demonstrated to regulate neuronal membrane excitability mediated by voltage-gated sodium channels [207].

However, new research concerning one of these diets, the Medium-Chain Triglyceride (MCT) KD, has recently demonstrated a compelling mechanism of action in seizure control [208] diet. These studies show that a fatty acid provided in the diet, decanoic acid (10:0), reduces seizures induced in hippocampal slices of rodent. Using the whole cell patch clamp with rat hippocampal slices, decanoic acid reduced excitatory postsynaptic currents by 38.9±5.5% at 52 µg/mL concentration and inhibited α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, which are a target for antiepileptic drugs. This inhibitory mechanism is specific to defined chemical structures, is effective against multiple AMPA subunit compositions, and is enhanced during synaptic activation. These results define how the MCT diet provides a way of controlling seizures by the diet, without the need for the production of ketones or for pharmacological intervention [208, 209].

Given that patients with AD show a higher incidence of seizures [210], KD may be a successful diet for its clinical treatment. Supporting evidence suggests that acute elevation of serum β-hydroxibutyrate (β-OHB) (one type of KB) through an oral dose of MCTs shows cognitive improvements in AD patients. A recent RCT in 20 patients (55-58 years) diagnosed with probable AD (n=15) or MCI (n=5) showed that acute administration of MCTs (40 g), which led to elevate β-OHB, was positively correlated to improved cognitive function [211]. Another clinical trial performed in 152 patients with mild to moderate AD [212] compared the effect of Axona®, a medical food containing a formulation of MCTs, or placebo and found that cognitive scores remained stabilized in the Axona® group, while the placebo groups presented a decline in cognition, but only among Apoε4(-) subjects. Although, Axona® formulation has been reported to be well-tolerated in normal elderly volunteers, the proposed cognitive effect is uncertain in non-demented elderly people. Importantly, all these cognitive responses to increased energetic substrates were strongly dependent on APOE genotype [213].

**Multicomponent diets**

The important role of diets and healthy lifestyle in the prevention of vascular disease development is widely accepted. Already 30 years ago pioneering studies on Greenland Eskimos indicated that intake of long chain ω-3 PUFAs from fish and wildfowl had protective effects against CVD [214, 215]. More recently, the Mediterranean diet containing fish, olive oil and nuts as important lipid containing components, has been shown in several prospective worldwide studies to be inversely associated with CVD [216] and to have a strong protective function against hypertension, obesity, and AD risks [4, 217-219].

Dietary lipids are also starting to be highly recognized in nutrition thanks to their direct actions on synaptic function and cognitive processes [220-225]. Contrarily, diets high in saturated fat are becoming notorious for reducing molecular substrates that support cognitive processing and increasing the risk of neurological dysfunction in both animals and humans [226-228]. Dietary factors can affect multiple brain processes by regulating neurotransmitter pathways, synaptic transmission, membrane fluidity and signal-transduction pathways. Recent data published by the group of Kiliaan et al. [229-232] and its new preliminary data in mice models for AD and vascular impairment, have shown that the treatment with multicomponent diets promotes neuroprotection by decreasing inflammation, restoring cerebral blood flow and volume, inhibiting neurodegeneration, and enhancing neural plasticity by increasing neurogenesis. In particular, they [229] showed that a specific combination diet (FortasynTM) containing membrane precursors such as ω-3 fatty acids and uridine monophosphate plus cofactors for membrane synthesis was able to inhibit/reverse the early functional connectivity reduction and cerebral blood flow (CBF) impairment in mice (both parameters were apparent already before cognitive decline).

Thus, diet may serve as preventive strategy at very early, non-symptomatic phases of AD, especially because there are no currently effective treatments for AD. Therefore, future research should focus on the early, asymptomatic phase of the disease especially on the (cardio) vascular risk factors like atherosclerosis, hypertension, obesity and T2DM being modifiable via changes in lifestyle factors such as diet.

**Exercise**

Gradual and progressive memory decline is often one of the earliest hallmarks in AD which can strongly influence the quality of life of an individual. Several lifestyle factors may interfere with the rate of cognitive decline in the elderly such as diet and physical activity.

The Study of Elderly’s Memory impairment and Associated Risk factors (SEMAR) has been set up in Indonesia and included 719 participants (aged 52-99 years) from different ethnic backgrounds in rural and urban Java (Jakarta, Citengah and Yogyakarta) (unpublished data). These cohorts as well as other similar cohorts in China, Netherlands, UK and USA, have recently been set up to investigate whether lifestyle factors in different ethnic/cultural cohorts were associated with a reduced risk of dementia (ongoing study) and found that the combination of exercise and eating fruit had a cumulative effect in reducing dementia risk in Indonesia people (unpublished data)

Many observational studies [233, 234] have showed a reduced risk of dementia in people who exercise. For instance, in Indonesia it was found that older people who engaged in sports had a halved risk of dementia [234], which was similar to data from the US and other countries [235]. However, several reviews have also showed that only 50% of the studies including an exercise intervention showed cognitive improvement in older people [233, 234] which might be due to poor adherence to the program. Similarly, the group of Hogervorst [234] found that resistance band (muscle strength) exercises 2-3 times/week for 20-30min improved memory function. In addition, exercise may be effective as a preventive activity as it can lower blood pressure and total cholesterol, can reduce abdominal fat and improve immune and lung function, as well as improve cardiovascular function, which improves CBF. As discussed previously, all these factors may be implicated in dementia. Importantly, exercise can also directly promote outgrowth of nerve cells which allows better communication between brain cells, which is often reduced in dementia [233]. Even in people who have already developed dementia, walking and muscle strengthening exercises are likely to have positive effects on cognitive abilities [234].

In conclusion, risk factors for AD are similar to those for CVD (heart), such as high blood pressure, smoking, high cholesterol and obesity and need to be treated in midlife at the latest to reduce the risk of dementia later in life. A multi-disciplinary change in lifestyles (combining exercise with healthy diets) with a focus on midlife is the most important factor for prevention of dementia. Therefore, changing the lifestyle to a healthier one which includes exercise and a healthy diet can reduce the risk for both heart disease and dementia.

**Methodological challenges in nutritional interventions on cognition** Epidemiological studies have shown that a lower risk of dementia or cognitive decline is associated with diets relatively low in energy [236] but rich in several key nutrients and food derived non-nutrient bioactives, including long-chain ω-3 PUFA [237, 238], vitamins B [239], antioxidants such as vitamins C, E [240] and carotenoids [241], and polyphenols [242]. However, most RCTs that have administered these dietary components as supplements have yielded disappointing results on cognition so far, [172, 180, 243]. There is, however, some notable interest, particularly in the Memory Improvement with DHA Study (MIDAS) [244], the Souvenaid® combination of nutrients in mild AD [245-247], and the Prevention with Mediterranean Diet (PREDIMED) study [248]. Thus, epidemiological data and these “success stories” from a limited number of RCTs, provide the justification and valuable methodological insight. In addition, they could be used in combination with the implementation of more robust ‘fit-for-purpose’ RCTs to demonstrate the impact of diet on cognition in older persons. Such interventions should be carefully powered and of adequate duration (chosen based on physiological insights into likely changes in the primary outcome measures during the intervention period) in order to prevent false negative findings. Three further aspects should be considered: 1) improving inclusion criteria in RCTs, 2) optimizing the composition of the nutritional supplement or the diet to be evaluated, and 3) defining more sensitive primary and secondary outcomes which are also important methodological considerations that will be discussed below.

Identification of individuals at high risk of cognitive decline or dementia, who should be included in RCTs assessing the impact of nutrition, who are likely to be sensitive and gain most benefit from the intervention should be based on early markers of disease progression, low dietary intake or blood levels of selected dietary components of interest, or genetic characteristics. The natural history of the pathophysiology of AD spreads over decades during which Aβ accumulates in the brain before the first cognitive symptoms appear [249, 250] raising the question of the optimal window for prevention or the progression from the preclinical, ‘at-risk’ phase to a clinical diagnosis of disease. It is virtually impossible to demonstrate the efficacy of primary prevention in regard to cognitive decline. Thus, the main target of RCTs should be the secondary prevention, at a very early stage of cognitive decline. The MIDAS included middle-aged adults (aged ˃55 years) with a subjective memory complaint and preserved general cognitive function but a logical memory baseline score lower than that of normal younger adults [244] to explore the effect of DHA consumption (900 mg/day) for 24 weeks. These individuals also had low regular fish consumption, less than 200 mg/day DHA. After completion of the trial, those receiving DHA, scored significantly higher on several tests of memory than the control group. The use of genetic variation as inclusion/exclusion criteria could also be considered, since several epidemiological studies and at least one RCT have suggested that the benefit of supplementation with DHA on cognition could be limited to non-carriers of the ε4 allele of the APOE4 gene, the main genetic risk factor for AD [251].

Epidemiology also allows characterization of healthy diets providing optimal combinations of foods and nutrients that are associated with better cognitive performance [252], providing the rationale for RCTs using combinations of supplements rather than single nutrients. The most famous example is the Mediterranean diet, which has been associated with lower risks of dementia or cognitive decline in several epidemiological studies, mostly in Europe and the US [2, 3, 253]. However, there is great heterogeneity in the definition of the “Mediterranean diet” between studies especially in non-Mediterranean countries. The PREDIMED NAVARRA RCT in Spain, demonstrated that randomized participants who followed a Mediterranean diet enriched with virgin olive oil or nuts scored significantly better than the control group following a low-fat diet on a global cognitive score 6.5 years later [248]. Few RCTs have evaluated the impact of multivitamin supplements on cognition [254]. For instance, Souvenaid® which contains ω-3 PUFA (EPA and DHA), vitamins B, a mixture of antioxidants, and uridine monophosphate (UMP), was formulated to improve synapse formation and function [255, 256]. A 24-week RCT conducted in patients with mild AD showed that the group receiving Souvenaid® scored significantly better than the placebo group on the memory domain of the neuropsychological test battery, the primary outcome [247]. The study also showed improvement on measures of functional connectivity [247], functional brain network organization [222], and sustained memory improvement until 48 weeks in an open label extension study [245]. This was the second study in mild AD with this intervention and confirmed the results of a proof-of-concept study which showed improved memory performance after 12 weeks [246]. As these studies were conducted in subjects with early AD, more research is needed to define the optimal combination and doses of nutrients that could contribute to delay cognitive decline in older persons without AD diagnosis.

In the case of EPA+DHA, vitamins D and B, although there is relatively consistent epidemiological evidence to exhibit their independent impacts on cognition, RCTs have generally failed to demonstrate any efficacy.

Identification of relevant and sensitive biomarkers of disease progression, based on knowledge of the specific molecular and physiological targets of the intervention of interest, can optimize the choice of primary and secondary outcomes in RCTs. MRI and fMRI can provide evidence of the impact of nutrients on brain structure and function The rate of brain atrophy was the primary outcome of the Hcy and vitamins B effect in cognitive impairment (VITACOG study) [167] which found that vitamin B intake in the active treatment group was associated with 30% less brain atrophy per year than in those receiving the placebo. The effect on brain atrophy and cognitive function was mainly observed in those with higher baseline Hcy levels, which were lowered by vitamin B treatment [167, 171]. However, some RCTs have yielded discordant results regarding their impact on mechanisms of action and cognition. The concentration of F2-isoprostane in CSF, a marker of oxidative stress (lipid peroxidation), has been proposed as a sensitive but not specific biomarker of age-related brain injury [257]. In an RCT, 78 patients with mild to moderate AD were randomized to receive a high dose antioxidant mixture (800 IU/d vitamin E, 500 mg/d vitamin C, and 900 mg/day α-lipoic acid) or 400 mg/d Coenzyme Q, another antioxidant compound, or a placebo [258]. After 16 weeks, those receiving the antioxidant mixture had significantly decreased F2-isoprostanes in CSF as expected, but had an accelerated cognitive decline. Thus, biomarkers should always be used in combination with cognitive outcomes.

This lack of positive results in RCTs may be due to too short trial duration, not appropriate target group, use of an inadequate dose, lack of efficacy of single nutrients and/or not sufficiently sensitive methodology to measure the outcomes. However, the identification of all these limitations will allow a better performance of future intervention trials. In addition, there is still need for well-designed trials that: a) have long intervention periods (at least >1.5 year), b) target at risk groups (mild cognitively impaired or nutrient deficient subjects), c) use harmonized cognitive test batteries, d) include biomarkers and/or imaging measures, e) use a multi-nutrient or food pattern approach or a multi-domain approach, and f) whose design is aligned with specific mechanisms. Findings from epidemiological studies can be used to design more efficient RCTs assessing the impact of combinations of nutrients in well-targeted individuals, using both biomarkers and cognitive assessment as outcomes (Table 1).

**Conclusion**

Decline in cognitive abilities with age occurs in healthy individuals throughout the adult lifespan. Moreover, the line between normal and pathological aging is not well-defined as neurological diseases start years before any clinical symptoms arise. Several health conditions such as CVD, diabetes or obesity are closely related to cognition. Therefore, when identifying dietary approaches to promote healthy brain aging a holistic approach should be considered including nutrition, exercise and other lifestyle factors, which not only target the brain but also overall cardio-metabolic health (Fig.1)

The mechanisms associated with normal aging, including oxidative stress, neuroinflammation and vascular dysfunction are the same as those contributing to the development of neurological diseases. However, in these pathological conditions, the mechanisms contributing to aging are exacerbated and triggered by different factors which might be genetic or environmental.

Preclinical studies in animals have consistently demonstrated the positive impact of several dietary components on cognitive performance and epidemiological studies have showed successful association of select dietary patterns with cognitive status. Particularly there is reasonable evidence that consuming Mediterranean-style diets protects against cognitive impairment. RCTs approaches have showed mixed results with intervention using single dietary components being generally disappointing while some multi-nutrient/non-nutrient interventions have yielded more encouraging results. These observations are consistent with the results from epidemiological studies indicating that an adherence to dietary patterns, rather than adequate intake of single dietary components may be the most effective means of protecting against cognitive decline. A major objective of future research is to define the nutritional requirement for healthy cognitive aging, and to translate these into effective dietary recommendations.

RCTs are the gold standard to probe the efficacy of drugs but it may not be the same for dietary components. In terms of primary prevention, it is logistically difficult to establish the effect of nutrition on cognition through RCTs which would require participants follow up for potentially decades. In terms of secondary prevention, targeting individuals at high risk of cognitive decline and learning from epidemiology as suggested in the last section of this review should allow a relatively rapid impact on cognition to be established.

Finally, it is the aim of this group to continue with the revision of the state of the art on nutrition for the aging brain by organizing a follow-up workshop. In particular, mechanisms of aging and their interaction with nutrients will be revisited, and new avenues and mechanisms of cognitive aging that may be influenced by nutrition will be identified.

Figure 1: Overview of links between lifestyle interventions on cognition and healthy brain function during aging.



**Acknowledgments**

The workshop ‘Nutrition for the Ageing Brain: Towards Evidence of an Optimal Diet’ was organized with funds from the ILSI Europe Nutrition and Mental Performance Task Force. Industry members of this task force are listed on the ILSI Europe website at www.ilsi.eu. For further information about ILSI Europe, please email info@ilsieurope.be or call +32 2 771 00 14. This review was prepared taken into account the presentations at the workshop mentioned in the abstract and was conducted by an expert group of ILSI Europe. The opinions expressed herein and the conclusions of this article do not necessarily represent either the views of ILSI Europe or those of its member companies. All authors read and approved the final manuscript.

**References**

[1] European Commission, Eurostat (2012) Active ageing and solidarity between generations. A statistical portrait of the European Union. 1-147.

[2] van de Rest O, Berendsen AA, Haveman-Nies A, de Groot LC (2015) Dietary patterns, cognitive decline, and dementia: a systematic review. *Adv Nutr* **6**, 154-168.

[3] Feart C, Samieri C, Barberger-Gateau P (2010) Mediterranean diet and cognitive function in older adults. *Curr Opin Clin Nutr Metab Care* **13**, 14-18.

[4] Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA (2009) Mediterranean diet and mild cognitive impairment. *Arch Neurol* **66**, 216-225.

[5] Stangl D, Thuret S (2009) Impact of diet on adult hippocampal neurogenesis. *Genes Nutr* **4**, 271-282.

[6] Townsend KP, Pratico D (2005) Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. *FASEB J* **19**, 1592-1601.

[7] Lee WH, Loo CY, Bebawy M, Luk F, Mason RS, Rohanizadeh R (2013) Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. *Curr Neuropharmacol* **11**, 338-378.

[8] Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology* **64**, 277-281.

[9] Beydoun MA, Beydoun HA, Wang Y (2008) Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. *Obes Rev* **9**, 204-218.

[10] Loef M, Walach H (2013) Midlife obesity and dementia: meta-analysis and adjusted forecast of dementia prevalence in the United States and China. *Obesity (Silver Spring)* **21**, 51-55.

[11] Nepal B, Brown LJ, Anstey KJ (2014) Rising midlife obesity will worsen future prevalence of dementia. *PLoS One* **9**, 99305.

[12] Greenwood CE (2003) Dietary carbohydrate, glucose regulation, and cognitive performance in elderly persons. *Nutr Rev* **61**, S68-74.

[13] Greenwood CE, Winocur G (2005) High-fat diets, insulin resistance and declining cognitive function. *Neurobiol Aging* **26 Suppl 1**, 42-45.

[14] Salthouse T (2010) Major issues in cognitive aging. *Oxford University Press*.

[15] Wesnes KA, T W (2000) Treatment of age-associated memory impairment. In: N Qizilbash, L Schneider, H Chui, P Tariot, H Brodaty, J Kaye, T Erkinjuntti (Eds.). Evidence-Based Dementia Practice: A practical guide to diagnosis and management (with internet updates). *Blackwell Science Publications* 639-652.

[16] Wesnes KA, Edgar CJ (2014) The role of human cognitive neuroscience in drug discovery for the dementias. *Curr Opin Pharmacol* **14**, 62-73.

[17] Wesnes K, Lenderking W (2012) The transition of cognitive decline from normal ageing to mild cognitive impairment and Alzheimer’s disease. *J Nutr Health Aging* **16**.

[18] Crook TH BR, Ferris SH, Whitehouse P, Cohen GD, Gershon S (1986) Age-associated memory impairment: Proposed diagnostic criteria and measures of clinical change - Report of a National Institute of Mental Health work group. *Dev Neuropsychol* **2**, 261-276.

[19] Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC (1991) Effects of phosphatidylserine in age-associated memory impairment. *Neurology* **41**, 644-649.

[20] O’Brien J (1999) Age-associated memory impairment and related disorders. *Adv Psychiatr Treat* **5**, 279-287.

[21] Cummings JL, Morstorf T, Zhong K (2014) Alzheimer's disease drug-development pipeline: few candidates, frequent failures. *Alzheimers Res Ther* **6**, 37.

[22] Becker RE, Greig NH, Giacobini E (2008) Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? *J Alzheimers Dis* **15**, 303-325.

[23] Mullard A (2012) Sting of Alzheimer's failures offset by upcoming prevention trials. *Nat Rev Drug Discov* **11**, 657-660.

[24] Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurol* **6**, 734-746.

[25] Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: a new lexicon. *Lancet Neurol* **9**, 1118-1127.

[26] Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 270-279.

[27] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 280-292.

[28] Kozauer N, Katz R (2013) Regulatory innovation and drug development for early-stage Alzheimer's disease. *N Engl J Med* **368**, 1169-1171.

[29] Jack CR, Jr., Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 257-262.

[30] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 263-269.

[31] McKhann GM (2011) Changing concepts of Alzheimer disease. *JAMA* **305**, 2458-2459.

[32] Giaccone G, Arzberger T, Alafuzoff I, Al-Sarraj S, Budka H, Duyckaerts C, Falkai P, Ferrer I, Ironside JW, Kovacs GG, Meyronet D, Parchi P, Patsouris E, Revesz T, Riederer P, Rozemuller A, Schmitt A, Winblad B, Kretzschmar H (2011) New lexicon and criteria for the diagnosis of Alzheimer's disease. *Lancet Neurol* **10**, 298-299; author reply 300-291.

[33] Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol* **9**, 119-128.

[34] Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. *Nat Rev Drug Discov* **9**, 560-574.

[35] Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nat Rev Neurol* **6**, 131-144.

[36] Herholz K, Ebmeier K (2011) Clinical amyloid imaging in Alzheimer's disease. *Lancet Neurol* **10**, 667-670.

[37] Perneczky R, Alexopoulos P, Kurz A (2014) Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. *Trends Mol Med* **20**, 8-15.

[38] Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Forstl H, Kurz A, Alexopoulos P (2011) CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. *Neurology* **77**, 35-38.

[39] Perneczky R, Guo LH, Kagerbauer SM, Werle L, Kurz A, Martin J, Alexopoulos P (2013) Soluble amyloid precursor protein beta as blood-based biomarker of Alzheimer's disease. *Transl Psychiatry* **3**, e227.

[40] Benetos A, Watfa G, Hanon O, Salvi P, Fantin F, Toulza O, Manckoundia P, Agnoletti D, Labat C, Gautier S (2012) Pulse wave velocity is associated with 1-year cognitive decline in the elderly older than 80 years: the PARTAGE study. *J Am Med Dir Assoc* **13**, 239-243.

[41] Khalil Z, LoGiudice D, Khodr B, Maruff P, Masters C (2007) Impaired peripheral endothelial microvascular responsiveness in Alzheimer's disease. *J Alzheimers Dis* **11**, 25-32.

[42] Eurostat statistics database, WHO Global Infobase, Organisation for economic co-operation and development (2012) Health at a glance, Europe 2012: overweight and obesity among adults. 62-63.

[43] Alzheimer’s Disease International (2009) World Alzheimer report. The global prevalence of dementia. 1-96.

[44] Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB (2004) The metabolic syndrome, inflammation, and risk of cognitive decline. *JAMA* **292**, 2237-2242.

[45] Cheng G, Huang C, Deng H, Wang H (2012) Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. *Intern Med J* **42**, 484-491.

[46] Freeman LR, Haley-Zitlin V, Rosenberger DS, Granholm AC (2014) Damaging effects of a high-fat diet to the brain and cognition: a review of proposed mechanisms. *Nutr Neurosci* **17**, 241-251.

[47] Elias MF, Robbins MA, Budge MM, Abhayaratna WP, Dore GA, Elias PK (2009) Arterial pulse wave velocity and cognition with advancing age. *Hypertension* **53**, 668-673.

[48] Picano E, Bruno RM, Ferrari GF, Bonuccelli U (2014) Cognitive impairment and cardiovascular disease: so near, so far. *Int J Cardiol* **175**, 21-29.

[49] Kiliaan AJ, Arnoldussen IA, Gustafson DR (2014) Adipokines: a link between obesity and dementia? *Lancet Neurol* **13**, 913-923.

[50] Song J, Lee JE (2013) Adiponectin as a new paradigm for approaching Alzheimer's disease. *Anat Cell Biol* **46**, 229-234.

[51] Lamport DJ, Lawton CL, Mansfield MW, Dye L (2009) Impairments in glucose tolerance can have a negative impact on cognitive function: a systematic research review. *Neurosci Biobehav Rev* **33**, 394-413.

[52] Calvo-Ochoa E, Arias C (2015) Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models. *Diabetes Metab Res Rev* **31**, 1-13.

[53] De Felice FG (2013) Alzheimer's disease and insulin resistance: translating basic science into clinical applications. *J Clin Invest* **123**, 531-539.

[54] Park CR, Seeley RJ, Craft S, Woods SC (2000) Intracerebroventricular insulin enhances memory in a passive-avoidance task. *Physiol Behav* **68**, 509-514.

[55] Williamson R, McNeilly A, Sutherland C (2012) Insulin resistance in the brain: an old-age or new-age problem? *Biochem Pharmacol* **84**, 737-745.

[56] Craft S, Cholerton B, Baker LD (2013) Insulin and Alzheimer's disease: untangling the web. *J Alzheimers Dis* **33 Suppl 1**, S263-275.

[57] Kuwabara T, Kagalwala MN, Onuma Y, Ito Y, Warashina M, Terashima K, Sanosaka T, Nakashima K, Gage FH, Asashima M (2011) Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb. *EMBO Mol Med* **3**, 742-754.

[58] Bingham EM, Hopkins D, Smith D, Pernet A, Hallett W, Reed L, Marsden PK, Amiel SA (2002) The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. *Diabetes* **51**, 3384-3390.

[59] Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV (2001) Insulin promotes rapid delivery of N-methyl-D- aspartate receptors to the cell surface by exocytosis. *Proc Natl Acad Sci U S A* **98**, 3561-3566.

[60] Andro M, Le Squere P, Estivin S, Gentric A (2013) Anaemia and cognitive performances in the elderly: a systematic review. *Eur J Neurol* **20**, 1234-1240.

[61] Lucca U, Tettamanti M, Mosconi P, Apolone G, Gandini F, Nobili A, Tallone MV, Detoma P, Giacomin A, Clerico M, Tempia P, Guala A, Fasolo G, Riva E (2008) Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "Health and Anemia" study. *PLoS One* **3**, e1920.

[62] Chakrabarti S, Munshi S, Banerjee K, Thakurta IG, Sinha M, Bagh MB (2011) Mitochondrial dysfunction during brain aging: role of oxidative stress and modulation by antioxidant supplementation. *Aging Dis* **2**, 242-256.

[63] Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. *Biochim Biophys Acta* **1842**, 1240-1247.

[64] Perry VH, Holmes C (2014) Microglial priming in neurodegenerative disease. *Nat Rev Neurol* **10**, 217-224.

[65] Perry VH, Cunningham C, Holmes C (2007) Systemic infections and inflammation affect chronic neurodegeneration. *Nat Rev Immunol* **7**, 161-167.

[66] Perry VH (2004) The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. *Brain Behav Immun* **18**, 407-413.

[67] Schroder K, Sweet MJ, Hume DA (2006) Signal integration between IFNgamma and TLR signalling pathways in macrophages. *Immunobiology* **211**, 511-524.

[68] Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD (2009) Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. *Biol Psychiatry* **66**, 407-414.

[69] Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD (2008) Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. *Biol Psychiatry* **63**, 1022-1029.

[70] Hannestad J, Gallezot JD, Schafbauer T, Lim K, Kloczynski T, Morris ED, Carson RE, Ding YS, Cosgrove KP (2012) Endotoxin-induced systemic inflammation activates microglia: [(1)(1)C]PBR28 positron emission tomography in nonhuman primates. *Neuroimage* **63**, 232-239.

[71] Chapoval AI, Kamdar SJ, Kremlev SG, Evans R (1998) CSF-1 (M-CSF) differentially sensitizes mononuclear phagocyte subpopulations to endotoxin in vivo: a potential pathway that regulates the severity of gram-negative infections. *J Leukoc Biol* **63**, 245-252.

[72] Rankine EL, Hughes PM, Botham MS, Perry VH, Felton LM (2006) Brain cytokine synthesis induced by an intraparenchymal injection of LPS is reduced in MCP-1-deficient mice prior to leucocyte recruitment. *Eur J Neurosci* **24**, 77-86.

[73] Bhattacharyya S, Ghosh S, Dasgupta B, Mazumder D, Roy S, Majumdar S (2002) Chemokine-induced leishmanicidal activity in murine macrophages via the generation of nitric oxide. *J Infect Dis* **185**, 1704-1708.

[74] Greter M, Lelios I, Pelczar P, Hoeffel G, Price J, Leboeuf M, Kundig TM, Frei K, Ginhoux F, Merad M, Becher B (2012) Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. *Immunity* **37**, 1050-1060.

[75] Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, Barrow AD, Diamond MS, Colonna M (2012) IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. *Nat Immunol* **13**, 753-760.

[76] Gomez-Nicola D, Fransen NL, Suzzi S, Perry VH (2013) Regulation of microglial proliferation during chronic neurodegeneration. *J Neurosci* **33**, 2481-2493.

[77] Nicholson AM, Baker MC, Finch NA, Rutherford NJ, Wider C, Graff-Radford NR, Nelson PT, Clark HB, Wszolek ZK, Dickson DW, Knopman DS, Rademakers R (2013) CSF1R mutations link POLD and HDLS as a single disease entity. *Neurology* **80**, 1033-1040.

[78] Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. *Mech Ageing Dev* **128**, 92-105.

[79] Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM (2013) Neuroinflammatory phenotype in early Alzheimer's disease. *Neurobiol Aging* **34**, 1051-1059.

[80] Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B (2012) Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* **380**, 37-43.

[81] Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic inflammation and disease progression in Alzheimer disease. *Neurology* **73**, 768-774.

[82] Holmes C, Cunningham C, Zotova E, Culliford D, Perry VH (2011) Proinflammatory cytokines, sickness behavior, and Alzheimer disease. *Neurology* **77**, 212-218.

[83] Caberlotto L, Lauria M, Nguyen TP, Scotti M (2013) The central role of AMP-kinase and energy homeostasis impairment in Alzheimer’s disease: a multifactor network analysis. *PLoS One* **8**, e78919.

[84] Caberlotto L, Nguyen TP (2014) A systems biology investigation of neurodegenerative dementia reveals a pivotal role of autophagy. *BMC Syst Biol* **8**, 1-15.

[85] Caberlotto L, Nguyen TP (2015) Alzheimer’s and Type 2 Diabetes: network analysis across clinical boundaries. *Abstract presented at the ADPD meeting 2015*.

[86] Mattson MP (2012) Energy intake and exercise as determinants of brain health and vulnerability to injury and disease. *Cell Metab* **16**, 706-722.

[87] Martin B, Mattson MP, Maudsley S (2006) Caloric restriction and intermittent fasting: two potential diets for successful brain aging. *Ageing Res Rev* **5**, 332-353.

[88] Roman-Viñas B, Serra-Majem L (2014) Diet and healthy patterns in the elderly. *Curr Nutr Rep* **3**, 69-87.

[89] Maillot M, Issa C, Vieux F, Lairon D, Darmon N (2011) The shortest way to reach nutritional goals is to adopt Mediterranean food choices: evidence from computer-generated personalized diets. *Am J Clin Nutr* **94**, 1127-1137.

[90] Sofi F, Abbate R, Gensini GF, Casini A (2010) Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. *Am J Clin Nutr* **92**, 1189-1196.

[91] Bach-Faig A, Berry EM, Lairon D, Reguant J, Trichopoulou A, Dernini S, Medina FX, Battino M, Belahsen R, Miranda G, Serra-Majem L (2011) Mediterranean diet pyramid today. Science and cultural updates. *Public Health Nutr* **14**, 2274-2284.

[92] Prins ND, Scheltens P (2015) White matter hyperintensities, cognitive impairment and dementia: an update. *Nat Rev Neurol* **11**, 157-165.

[93] Chen RL (2011) Is it appropriate to use albumin CSF/plasma ratio to assess blood brain barrier permeability? *Neurobiol Aging* **32**, 1338-1339.

[94] Bowman GL (2012) Ascorbic acid, cognitive function, and Alzheimer's disease: a current review and future direction. *Biofactors* **38**, 114-122.

[95] Lehmann M, Regland B, Blennow K, Gottfries CG (2003) Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. *Dement Geriatr Cogn Disord* **16**, 145-150.

[96] Bowman GL, Silbert LC, Howieson D, Dodge HH, Traber MG, Frei B, Kaye JA, Shannon J, Quinn JF (2012) Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. *Neurology* **78**, 241-249.

[97] Bowman GL, Dodge HH, Mattek N, Barbey AK, Silbert LC, Shinto L, Howieson DB, Kaye JA, Quinn JF (2013) Plasma omega-3 PUFA and white matter mediated executive decline in older adults. *Front Aging Neurosci* **5**, 92.

[98] Hercberg S, Castetbon K, Czernichow S, Malon A, Mejean C, Kesse E, Touvier M, Galan P (2010) The Nutrinet-Sante Study: a web-based prospective study on the relationship between nutrition and health and determinants of dietary patterns and nutritional status. *BMC Public Health* **10**, 1-6.

[99] Scalbert A, Manach C, Morand C, Remesy C, Jimenez L (2005) Dietary polyphenols and the prevention of diseases. *Crit Rev Food Sci Nutr* **45**, 287-306.

[100] Arts IC, Hollman PC (2005) Polyphenols and disease risk in epidemiologic studies. *Am J Clin Nutr* **81**, 317S-325S.

[101] van Dam RM, Naidoo N, Landberg R (2013) Dietary flavonoids and the development of type 2 diabetes and cardiovascular diseases: review of recent findings. *Curr Opin Lipidol* **24**, 25-33.

[102] Cassidy A, Mukamal KJ, Liu L, Franz M, Eliassen AH, Rimm EB (2013) High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. *Circulation* **127**, 188-196.

[103] Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, Ryder JJ, Hall WL, Cassidy A (2008) Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* **88**, 38-50.

[104] Pujos-Guillot E, Hubert J, Martin JF, Lyan B, Quintana M, Claude S, Chabanas B, Rothwell JA, Bennetau-Pelissero C, Scalbert A, Comte B, Hercberg S, Morand C, Galan P, Manach C (2013) Mass spectrometry-based metabolomics for the discovery of biomarkers of fruit and vegetable intake: citrus fruit as a case study. *J Proteome Res* **12**, 1645-1659.

[105] Scalbert A, Brennan L, Manach C, Andres-Lacueva C, Dragsted LO, Draper J, Rappaport S, Van der Hooft JJJ, wishart D (2014) The food metabolome: a window over dietary exposure. *Am J Clin Nutr*, 1-23.

[106] Rothwell JA, Fillâtre Y, Martin JF, Lyan B, Pujos-Guillot E, Fezeu L, Hercberg S, Comte B, Galan P, Touvier M, Manach C (2014) New biomarkers of coffee consumption identified by the non-targeted metabolomic profiling of cohort study subjects *PLoS One* **9**, e93474.

[107] Akbaraly TN, Hininger-Favier I, Carriere I, Arnaud J, Gourlet V, Roussel AM, Berr C (2007) Plasma selenium over time and cognitive decline in the elderly. *Epidemiology* **18**, 52-58.

[108] Loef M, Schrauzer GN, Walach H (2011) Selenium and Alzheimer's disease: a systematic review. *J Alzheimers Dis* **26**, 81-104.

[109] Nuttall JR, Oteiza PI (2014) Zinc and the aging brain. *Genes Nutr* **9**, 379.

[110] Roussel AM, Andriollo-Sanchez M, Ferry M, Bryden NA, Anderson RA (2007) Food chromium content, dietary chromium intake and related biological variables in French free-living elderly. *Br J Nutr* **98**, 326-331.

[111] Krikorian R, Eliassen JC, Boespflug EL, Nash TA, Shidler MD (2010) Improved cognitive-cerebral function in older adults with chromium supplementation. *Nutr Neurosci* **13**, 116-122.

[112] McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT (2012) Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. *Am J Clin Nutr* **95**, 454-464.

[113] Zamora-Ros R, Rabassa M, Llorach R, Gonzalez CA, Andres-Lacueva C (2012) Application of dietary phenolic biomarkers in epidemiology: past, present, and future. *J Agric Food Chem* **60**, 6648-6657.

[114] Zamora-Ros R, Rabassa M, Cherubini A, Urpi-Sarda M, Llorach R, Bandinelli S, Ferrucci L, Andres-Lacueva C (2011) Comparison of 24-h volume and creatinine-corrected total urinary polyphenol as a biomarker of total dietary polyphenols in the Invecchiare InCHIANTI study. *Anal Chim Acta* **704**, 110-115.

[115] Zamora-Ros R, Rabassa M, Cherubini A, Urpi-Sarda M, Bandinelli S, Ferrucci L, Andres-Lacueva C (2013) High concentrations of a urinary biomarker of polyphenol intake are associated with decreased mortality in older adults. *J Nutr* **143**, 1445-1450.

[116] Rabassa M, Cherubini A, Zamora-Ros R, Urpi-Sarda M, Bandinelli S, Ferrucci L, Andres-Lacueva C (2015) Low Levels of a Urinary Biomarker of Dietary Polyphenol Are Associated with Substantial Cognitive Decline over a 3-Year Period in Older Adults: The Invecchiare in Chianti Study. *J Am Geriatr Soc* **63**, 938-946.

[117] Salminen A, Kaarniranta K (2012) AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. *Ageing Res Rev* **11**, 230-241.

[118] Peterson DW, George RC, F S, NE L, Anderson RA, Graves DJ, J L (2009) Cinnamon extracts inhibit Tau protein aggregation associated with Alzheimer’s disease in vitro. *J Alzheimers Dis* **17**, 585-596.

[119] Anderson RA, Qin B, Canini F, Poulet L, Roussel AM (2013) Cinnamon counteracts the negative effects of a high fat/high fructose diet on behavior, brain insulin signaling and Alzheimer-associated changes. *PLoS One* **8**, e83243.

[120] Llorach R, Garcia-Aloy M, Tulipani S, Vazquez-Fresno R, Andres-Lacueva C (2012) Nutrimetabolomic strategies to develop new biomarkers of intake and health effects. *J Agric Food Chem* **60**, 8797-8808.

[121] Williams RJ, Spencer JP (2012) Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. *Free Radic Biol Med* **52**, 35-45.

[122] Spencer JP (2008) Food for thought: the role of dietary flavonoids in enhancing human memory, learning and neuro-cognitive performance. *Proc Nutr Soc* **67**, 238-252.

[123] Del Rio D, Rodriguez-Mateos A, Spencer JP, Tognolini M, Borges G, Crozier A (2013) Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. *Antioxid Redox Signal* **18**, 1818-1892.

[124] Williams RJ, Spencer JP, C R-E (2004) Flavonoids: antioxidants or signalling molecules?. *Free Radic Biol Med.* **36**, 838-849.

[125] Cox CJ, Choudhry F, Peacey E, Perkinton MS, Richardson JC, Howlett DR, Lichtenthaler SF, Francis PT, Williams RJ (2015) Dietary (-)-epicatechin as a potent inhibitor of betagamma-secretase amyloid precursor protein processing. *Neurobiol Aging* **36**, 178-187.

[126] Macready AL, Butler LT, Kennedy OB, Ellis JA, Williams CM, Spencer JP (2010) Cognitive tests used in chronic adult human randomised controlled trial micronutrient and phytochemical intervention studies. *Nutr Res Rev* **23**, 200-229.

[127] Williams CM, El Mohsen MA, Vauzour D, Rendeiro C, Butler LT, Ellis JA, Whiteman M, Spencer JP (2008) Blueberry-induced changes in spatial working memory correlate with changes in hippocampal CREB phosphorylation and brain-derived neurotrophic factor (BDNF) levels. *Free Radic Biol Med* **45**, 295-305.

[128] Rendeiro C, Vauzour D, Rattray M, Waffo-Teguo P, Merillon JM, Butler LT, Williams CM, Spencer JP (2013) Dietary levels of pure flavonoids improve spatial memory performance and increase hippocampal brain-derived neurotrophic factor. *PLoS One* **8**, e63535.

[129] Rendeiro C, Vauzour D, Kean RJ, Butler LT, Rattray M, Spencer JPE, Williams CM (2012) Blueberry supplementation induces spatial memory improvements and region-specific regulation of hippocampal BDNF mRNA expression in young rats. *Psychopharmacology* **223**, 319-330.

[130] Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA (2010) Glial and neuronal control of brain blood flow. *Nature* **468**, 232-243.

[131] Toda N, Ayajiki K, Okamura T (2009) Cerebral blood flow regulation by nitric oxide in neurological disorders. *Can J Physiol Pharmacol* **87**, 581-594.

[132] Atochin DN, Huang PL (2011) Role of endothelial nitric oxide in cerebrovascular regulation. *Curr Pharm Biotechnol* **12**, 1334-1342.

[133] Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, Sies H, Kwik-Uribe C, Schmitz HH, Kelm M (2006) (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. *Proc Natl Acad Sci U S A* **103**, 1024-1029.

[134] Schroeter H, Heiss C, Spencer JP, Keen CL, Lupton JR, Schmitz HH (2010) Recommending flavanols and procyanidins for cardiovascular health: current knowledge and future needs. *Mol Aspects Med* **31**, 546-557.

[135] Rodriguez-Mateos A, Rendeiro C, Bergillos-Meca T, Tabatabaee S, George TW, Heiss C, Spencer JP (2013) Intake and time dependence of blueberry flavonoid-induced improvements in vascular function: a randomized, controlled, double-blind, crossover intervention study with mechanistic insights into biological activity. *Am J Clin Nutr* **98**, 1179-1191.

[136] Cotman CW, Berchtold NC, Christie LA (2007) Exercise builds brain health: key roles of growth factor cascades and inflammation. *Trends Neurosci* **30**, 464-472.

[137] Bechara RG, Kelly AM (2013) Exercise improves object recognition memory and induces BDNF expression and cell proliferation in cognitively enriched rats. *Behav Brain Res* **245**, 96-100.

[138] Spencer JP (2009) The impact of flavonoids on memory: physiological and molecular considerations. *Chem Soc Rev* **38**, 1152-1161.

[139] Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. *Nature* **399**, 601-605.

[140] Rameau GA, Tukey DS, Garcin-Hosfield ED, Titcombe RF, Misra C, Khatri L, Getzoff ED, Ziff EB (2007) Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the NMDA receptor regulates AMPA receptor trafficking and neuronal cell death. *J Neurosci* **27**, 3445-3455.

[141] Iadecola C, Pelligrino DA, Moskowitz MA, Lassen NA (1994) Nitric oxide synthase inhibition and cerebrovascular regulation. *J Cereb Blood Flow Metab* **14**, 175-192.

[142] Shabeeh H, Melikian N, Dworakowski R, Casadei B, Chowienczyk P, Shah AM (2013) Differential role of endothelial versus neuronal nitric oxide synthase in the regulation of coronary blood flow during pacing-induced increases in cardiac workload. *Am J Physiol Heart Circ Physiol* **304**, H1277-1282.

[143] Kelly PA, Thomas CL, Ritchie IM, Arbuthnott GW (1994) Cerebrovascular autoregulation in response to hypertension induced by NG-nitro-L-arginine methyl ester. *Neuroscience* **59**, 13-20.

[144] Lamport DJ, Pal D, Moutsiana C, Field DT, Williams CM, Spencer JP, Butler LT (2015) The effect of flavanol-rich cocoa on cerebral perfusion in healthy older adults during conscious resting state: a placebo controlled, crossover, acute trial. *Psychopharmacology (Berl)* **232**, 3227-3234.

[145] Bakker A, Kirwan CB, Miller M, Stark CE (2008) Pattern separation in the human hippocampal CA3 and dentate gyrus. *Science* **319**, 1640-1642.

[146] Yassa MA, Lacy JW, Stark SM, Albert MS, Gallagher M, Stark CE (2011) Pattern separation deficits associated with increased hippocampal CA3 and dentate gyrus activity in nondemented older adults. *Hippocampus* **21**, 968-979.

[147] Brickman AM, Khan UA, Provenzano FA, Yeung LK, Suzuki W, Schroeter H, Wall M, Sloan RP, Small SA (2014) Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults. *Nat Neurosci* **17**, 1798-1803.

[148] Corona G, Vauzour D, Hercelin J, Williams CM, Spencer JP (2013) Phenolic acid intake, delivered via moderate champagne wine consumption, improves spatial working memory via the modulation of hippocampal and cortical protein expression/activation. *Antioxid Redox Signal* **19**, 1676-1689.

[149] Mangialasche F, Xu W, Kivipelto M, Costanzi E, Ercolani S, Pigliautile M, Cecchetti R, Baglioni M, Simmons A, Soininen H, Tsolaki M, Kloszewska I, Vellas B, Lovestone S, Mecocci P (2011) Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. *Neurobiol Aging* **33**, 2282-2290.

[150] Barnard ND, Bush AI, Ceccarelli A, Cooper J, de Jager CA, Erickson KI, Fraser G, Kesler S, Levin SM, Lucey B, Morris MC, Squitti R (2014) Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. *Neurobiol Aging* **35 Suppl 2**, S74-78.

[151] Harrison FE, Bowman GL, Polidori MC (2014) Ascorbic acid and the brain: rationale for the use against cognitive decline. *Nutrients* **6**, 1752-1781.

[152] Levitt AJ, Karlinsky H (1992) Folate, vitamin B12 and cognitive impairment in patients with Alzheimer's disease. *Acta Psychiatr Scand* **86**, 301-305.

[153] Obeid R, Herrmann W (2006) Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. *FEBS Lett* **580**, 2994-3005.

[154] Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med* **346**, 476-483.

[155] Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. *N Engl J Med* **324**, 1149-1155.

[156] Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. *Arch Neurol* **55**, 1449-1455.

[157] O'Leary F, Allman-Farinelli M, Samman S (2012) Vitamin B12 status, cognitive decline and dementia: a systematic review of prospective cohort studies. *Br J Nutr* **108**, 1948-1961.

[158] Alzheimer's Disease International (2014) Nutrition and dementia. A review of available research. 1-88.

[159] Ford AH, Almeida OP (2012) Effect of homocysteine lowering treatment on cognitive function: a systematic review and meta-analysis of randomized controlled trials. *J Alzheimers Dis* **29**, 133-149.

[160] Malouf R, Areosa Sastre A (2003) Vitamin B12 for cognition. *Cochrane Database Syst Rev*, CD004326.

[161] Malouf R, Grimley Evans J (2008) Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. *Cochrane Database Syst Rev*, CD004514.

[162] Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD (2013) Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. *Proc Natl Acad Sci U S A* **110**, 9523-9528.

[163] Hankey GJ, Ford AH, Yi Q, Eikelboom JW, Lees KR, Chen C, Xavier D, Navarro JC, Ranawaka UK, Uddin W, Ricci S, Gommans J, Schmidt R, Almeida OP, van Bockxmeer FM, Group VTS (2013) Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis. *Stroke* **44**, 2232-2239.

[164] Walker JG, Batterham PJ, Mackinnon AJ, Jorm AF, Hickie I, Fenech M, Kljakovic M, Crisp D, Christensen H (2012) Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms--the Beyond Ageing Project: a randomized controlled trial. *Am J Clin Nutr* **95**, 194-203.

[165] de Lau LM, Smith AD, Refsum H, Johnston C, Breteler MM (2009) Plasma vitamin B12 status and cerebral white-matter lesions. *J Neurol Neurosurg Psychiatr* **80**, 149-157.

[166] Sachdev PS, Valenzuela M, Wang XL, Looi JC, Brodaty H (2002) Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. *Neurology* **58**, 1539-1541.

[167] Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H (2010) Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial. *PLoS One* **5**, e12244.

[168] Tangney CC, Aggarwal NT, Li H, Wilson RS, Decarli C, Evans DA, Morris MC (2011) Vitamin B12, cognition, and brain MRI measures: A cross-sectional examination. *Neurology* **77**, 1276-1282.

[169] Vogiatzoglou A, Refsum H, Johnston C, Smith SM, Bradley KM, de Jager C, Budge MM, Smith AD (2008) Vitamin B12 status and rate of brain volume loss in community-dwelling elderly. *Neurology* **71**, 826-832.

[170] Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. *Lancet* **369**, 208-216.

[171] de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD (2012) Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. *Int J Geriatr Psychiatry* **27**, 592-600.

[172] Clarke R, Bennett D, Parish S, Lewington S, Skeaff M, Eussen SJ, Lewerin C, Stott DJ, Armitage J, Hankey GJ, Lonn E, Spence JD, Galan P, de Groot LC, Halsey J, Dangour AD, Collins R, Grodstein F (2014) Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. *Am J Clin Nutr* **100**, 657-666.

[173] Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bonaa KH, Spence JD, Nygard O, Jamison R, Gaziano JM, Guarino P, Bennett D, Mir F, Peto R, Collins R (2010) Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37,485 individuals. *Arch Intern Med* **170**, 1622-1631.

[174] van der Wielen RPJ, Löwik MRH, van der Berg H, de Groot LC, Haller J, Moreiras O, WA vS (1995) Serum vitamin D concentrations among elderly people in Europe. *Lancet* **346**, 207–210.

[175] Brouwer-Brolsma EM, de Groot LC (2015) Vitamin D and cognition in older adults: an update of recent findings. *Curr Opin Clin Nutr Metab Care* **18**, 11-16.

[176] Balion C, Griffith LE, Strifler L, Henderson M, Patterson C, Heckman G, Llewellyn DJ, Raina P (2012) Vitamin D, cognition, and dementia: A systematic review and meta-analysis. *Neurology* **79**, 1397-1405.

[177] Janssen CI, Kiliaan AJ (2014) Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. *Prog Lipid Res* **53**, 1-17.

[178] van de Rest O, van Hooijdonk LW, Doets E, Schiepers OJ, Eilander A, de Groot LC (2012) B vitamins and n-3 fatty acids for brain development and function: review of human studies. *Ann Nutr Metab* **60**, 272-292.

[179] Lim W, Gammack J, Van Niekerk J, Dangour A (2006) Omega 3 fatty acid for the prevention of dementia. *Cochrane Database Syst Rev*, CD005379.

[180] Sydenham E, Dangour AD, Lim WS (2012) Omega 3 fatty acid for the prevention of cognitive decline and dementia. *Cochrane Database Syst Rev* **6**, CD005379.

[181] Mazereeuw G, Lanctot KL, Chau SA, Swardfager W, Herrmann N (2012) Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. *Neurobiol Aging* **33**, 1482.e1417-1482.e1429.

[182] Conklin SM, Gianaros PJ, Brown SM, Yao JK, Hariri AR, Manuck SB, Muldoon MF (2007) Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults. *Neurosci Lett* **421**, 209-212.

[183] Samieri C, Maillard P, Crivello F, Proust-Lima C, Peuchant E, Helmer C, Amieva H, Allard M, Dartigues JF, Cunnane SC, Mazoyer BM, Barberger-Gateau P (2012) Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe. *Neurology* **79**, 642-650.

[184] Tan ZS, Harris WS, Beiser AS, Au R, Himali JJ, Debette S, Pikula A, Decarli C, Wolf PA, Vasan RS, Robins SJ, Seshadri S (2012) Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. *Neurology* **78**, 658-664.

[185] Titova OE, Sjogren P, Brooks SJ, Kullberg J, Ax E, Kilander L, Riserus U, Cederholm T, Larsson EM, Johansson L, Ahlstrom H, Lind L, Schioth HB, Benedict C (2013) Dietary intake of eicosapentaenoic and docosahexaenoic acids is linked to gray matter volume and cognitive function in elderly. *Age (Dordr)* **35**, 1495-1505.

[186] Virtanen JK, Siscovick DS, Longstreth WT, Jr., Kuller LH, Mozaffarian D (2008) Fish consumption and risk of subclinical brain abnormalities on MRI in older adults. *Neurology* **71**, 439-446.

[187] Pottala JV, Yaffe K, Robinson JG, Espeland MA, Wallace R, Harris WS (2014) Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI Study. *Neurology* **82**, 435-442.

[188] Witte AV, Kerti L, Hermannstadter HM, Fiebach JB, Schreiber SJ, Schuchardt JP, Hahn A, Floel A (2013) Long-chain omega-3 fatty acids improve brain function and structure in older adults. *Cereb Cortex* **24**, 3059-3068.

[189] Zainuddin MS TS (2012) Nutrition, adult hippocampal neurogenesis and mental health. *Br Med Bull* **103**, 25.

[190] Murphy T, Thuret S (2014) The systemic milieu as a mediator of dietary influence on stem cell function during ageing. *Ageing Res Rev* **19**, 53-64.

[191] Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA (2011) Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. *Nature* **476**, 458-461.

[192] Mateus-Pinheiro A, Pinto L, Bessa JM, Morais M, Alves ND, Monteiro S, Patricio P, Almeida OF, Sousa N (2013) Sustained remission from depressive-like behavior depends on hippocampal neurogenesis. *Transl Psychiatry* **1**, e210.

[193] Murphy T, Dias GP, Thuret S (2014) Effects of diet on brain plasticity in animal and human studies: mind the gap. *Neural Plast* **2014**, 1-32.

[194] Maruszak A, Pilarski A, Murphy T, Branch N, Thuret S (2014) Hippocampal neurogenesis in Alzheimer's disease: is there a role for dietary modulation? *J Alzheimers Dis* **38**, 11-38.

[195] Wu P, Shen Q, Dong S, Xu Z, Tsien JZ, Hu Y (2008) Calorie restriction ameliorates neurodegenerative phenotypes in forebrain-specific presenilin-1 and presenilin-2 double knockout mice. *Neurobiol Aging* **29**, 1502-1511.

[196] Park SK, Prolla TA (2005) Lessons learned from gene expression profile studies of aging and caloric restriction. *Ageing Res Rev* **4**, 55-65.

[197] Steinman MQ, Crean KK, Trainor BC (2011) Photoperiod interacts with food restriction in performance in the Barnes maze in female California mice. *Eur J Neurosci* **33**, 361-370.

[198] Kuhla A, Lange S, Holzmann C, Maass F, Petersen J, Vollmar B, Wree A (2013) Lifelong caloric restriction increases working memory in mice. *PLoS ONE* **8**, e68778.

[199] Yilmaz N, Vural H, Yilmaz M, Sutcu R, Sirmali R, Hicyilmaz H, Delibas N (2011) Calorie restriction modulates hippocampal NMDA receptors in diet-induced obese rats. *J Recept Signal Transduct Res* **31**, 214-219.

[200] Atkins R (1972) Dr Atkins' diet revolution: the high calorie way to stay thin forever. *D. Mckay Co: New York, NY, USA*.

[201] Hartman AL, Gasior M, Vining EP, Rogawski MA (2007) The neuropharmacology of the ketogenic diet. *Pediatr Neurol* **36**, 281-292.

[202] Dashti HM, Al-Zaid NS, Mathew TC, Al-Mousawi M, Talib H, Asfar SK, Behbahani AI (2006) Long term effects of ketogenic diet in obese subjects with high cholesterol level. *Mol Cell Biochem* **286**, 1-9.

[203] Paoli A, Cenci L, Grimaldi KA (2011) Effect of ketogenic Mediterranean diet with phytoextracts and low carbohydrates/high-protein meals on weight, cardiovascular risk factors, body composition and diet compliance in Italian council employees. *Nutr J* **10**, 1-8.

[204] Baranano KW, Hartman AL (2008) The ketogenic diet: uses in epilepsy and other neurologic illnesses. *Curr Treat Options Neurol* **10**, 410-419.

[205] Paoli A, Rubini A, Volek JS, Grimaldi KA (2013) Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. *Eur J Clin Nutr* **67**, 789-796.

[206] Bough KJ, Rho JM (2007) Anticonvulsant mechanisms of the ketogenic diet. *Epilepsia* **48**, 43-58.

[207] Huffman J, Kossoff EH (2006) State of the ketogenic diet(s) in epilepsy. *Curr Neurol Neurosci Rep* **6**, 332-340.

[208] Chang P, Augustin K, Boddum K, Williams S, Sun M, Terschak JA, Hardege JD, Chen PE, Walker MC, Williams RS (2015) Seizure control by decanoic acid through direct AMPA receptor inhibition. *Brain*, 1-13.

[209] Chang P, Terbach N, Plant N, Chen PE, Walker MC, Williams RS (2013) Seizure control by ketogenic diet-associated medium chain fatty acids. *Neuropharmacology* **69**, 105-114.

[210] Palop JJ, Mucke L (2009) Epilepsy and cognitive impairments in Alzheimer disease. *Arch Neurol* **66**, 435-440.

[211] Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, Craft S (2004) Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. *Neurobiol Aging* **25**, 311-314.

[212] Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC (2009) Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. *Nutr Metab (Lond)* **6**, 1-25.

[213] Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA, Martins RN, Raskind M, Peskind E, Plymate S (2000) Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. *Ann N Y Acad Sci* **903**, 222-228.

[214] Bang HO, Dyerberg J, Nielsen AB (1971) Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. *Lancet* **1**, 1143-1145.

[215] Bang HO, Dyerberg J, Sinclair HM (1980) The composition of the Eskimo food in north western Greenland. *Am J Clin Nutr* **33**, 2657-2661.

[216] Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Martinez-Gonzalez MA (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* **368**, 1279-1290.

[217] Calton EK, James AP, Pannu PK, Soares MJ (2014) Certain dietary patterns are beneficial for the metabolic syndrome: reviewing the evidence. *Nutr Res* **34**, 559-568.

[218] Grosso G, Pajak A, Mistretta A, Marventano S, Raciti T, Buscemi S, Drago F, Scalfi L, Galvano F (2014) Protective role of the Mediterranean diet on several cardiovascular risk factors: evidence from Sicily, southern Italy. *Nutr Metab Cardiovasc Dis* **24**, 370-377.

[219] Koliaki C, Katsilambros N (2013) Dietary sodium, potassium, and alcohol: key players in the pathophysiology, prevention, and treatment of human hypertension. *Nutr Rev* **71**, 402-411.

[220] Kamphuis PJ, Scheltens P (2010) Can nutrients prevent or delay onset of Alzheimer's disease? *J Alzheimers Dis* **20**, 765-775.

[221] Wurtman RJ (2008) Synapse formation and cognitive brain development: effect of docosahexaenoic acid and other dietary constituents. *Metabolism* **57 Suppl 2**, S6-10.

[222] de Waal H, Stam CJ, Lansbergen MM, Wieggers RL, Kamphuis PJ, Scheltens P, Maestu F, van Straaten EC (2014) The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. *PLoS One* **9**, e86558.

[223] Shah RC, Kamphuis PJ, Leurgans S, Swinkels SH, Sadowsky CH, Bongers A, Rappaport SA, Quinn JF, Wieggers RL, Scheltens P, Bennett DA (2013) The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. *Alzheimers Res Ther* **5**, 1-9.

[224] van Wijk N, Broersen LM, de Wilde MC, Hageman RJ, Groenendijk M, Sijben JW, Kamphuis PJ (2014) Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination. *J Alzheimers Dis* **38**, 459-479.

[225] Shah RC (2011) Medical foods for Alzheimer's disease. *Drugs Aging* **28**, 421-428.

[226] Li W, Prakash R, Chawla D, Du W, Didion SP, Filosa JA, Zhang Q, Brann DW, Lima VV, Tostes RC, Ergul A (2013) Early effects of high-fat diet on neurovascular function and focal ischemic brain injury. *Am J Physiol Regul Integr Comp Physiol* **304**, R1001-1008.

[227] Gomez-Pinilla F (2008) Brain foods: the effects of nutrients on brain function. *Nat Rev Neurosci* **9**, 568-578.

[228] Wu A, Ying Z, Gomez-Pinilla F (2008) Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. *Neuroscience* **155**, 751-759.

[229] Zerbi V, Jansen D, Wiesmann M, Fang X, Broersen LM, Veltien A, Heerschap A, Kiliaan AJ (2014) Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease. *Neurobiol Aging* **35**, 600-613.

[230] Jansen D, Zerbi V, Janssen CI, van Rooij D, Zinnhardt B, Dederen PJ, Wright AJ, Broersen LM, Lutjohann D, Heerschap A, Kiliaan AJ (2014) Impact of a multi-nutrient diet on cognition, brain metabolism, hemodynamics, and plasticity in apoE4 carrier and apoE knockout mice. *Brain Struct Funct* **219**, 1841-1868.

[231] Jansen D, Zerbi V, Arnoldussen IA, Wiesmann M, Rijpma A, Fang XT, Dederen PJ, Mutsaers MP, Broersen LM, Lutjohann D, Miller M, Joosten LA, Heerschap A, Kiliaan AJ (2013) Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuropathology in AbetaPPswe-PS1dE9 mice. *PLoS One* **8**, e75393.

[232] Wiesmann M, Jansen D, Zerbi V, Broersen LM, Garthe A, Kiliaan AJ (2013) Improved spatial learning strategy and memory in aged Alzheimer AβPPswe/PS1dE9 mice on a multi-nutrient diet. *J Alzheimers Dis* **37**, 233-245.

[233] Clifford A BS, Hagervorst E, (2009) The effect of physical exercise on cognitive function in the elderly *In Q. Ganépy&R. Menard. Handbook of Cognitive Aging: Causes, Processes and Effects. New York Nova Science Publishers* 109-150.

[234] Hogervorst E, Clifford A, Stock J, Xin X, S B (2012) Exercise to Prevent Cognitive Decline and Alzheimer’s disease: For Whom, When, What, and (most importantly) How Much? . *Alzheimers Dis Parkinsonism* **2**, 1000e1117

[235] Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol* **10**, 819-828.

[236] Luchsinger JA, Tang MX, Shea S, Mayeux R (2002) Caloric intake and the risk of Alzheimer disease. *Arch Neurol***59**, 1258-1263.

[237] Cunnane SC, Plourde M, Pifferi F, Bégin M, Féart C, Barberger-Gateau P (2009) Fish, docosahexaenoic acid and Alzheimer's disease. *Prog Lipid Res* **48**, 239-256.

[238] Dacks PA, Shineman DW, Fillit HM (2013) Current evidence for the clinical use of long-chain polyunsaturated N-3 fatty acids to prevent age-related cognitive decline and Alzheimer’s disease. *J Nutr Health Aging* **17**, 240-251.

[239] Clarke R (2008) B-vitamins and prevention of dementia. *Proc Nutr Soc***67**, 75-81.

[240] Mangialasche F, Kivipelto M, Mecocci P, Rizzuto D, Palmer K, Winblad B, Fratiglioni L (2010) High plasma levels of vitamin E forms and reduced Alzheimer's disease risk in advanced age. *J Alzheimers Dis* **20**, 1029-1037.

[241] Li FJ, Shen L, Ji HF (2012) Dietary Intakes of Vitamin E, Vitamin C, and beta-Carotene and Risk of Alzheimer's Disease: A Meta-Analysis. *J Alzheimers Dis* **31**, 253-258.

[242] Joseph J, Cole G, Head E, Ingram D (2009) Nutrition, brain aging, and neurodegeneration. *J Neurosci* **29**, 12795-12801.

[243] Barberger Gateau P, Feart C, Samieri C, Letenneur L (2013) Dietary patterns and dementia In *Chronic Medical Disease and Cognitive Aging: Toward a Healthy Body and Brain*, Yaffe K, ed. Oxford University Press, New York, NY, pp. 197-224.

[244] Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N, Jr., Stedman M (2010) Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. *Alzheimers Dement* **6**, 456-464.

[245] Olde Rikkert MG, Verhey FR, Blesa R, von Arnim CA, Bongers A, Harrison J, Sijben J, Scarpini E, Vandewoude MF, Vellas B, Witkamp R, Kamphuis PJ, Scheltens P (2015) Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. *J Alzheimers Dis* **44**, 471-480.

[246] Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, Twisk JW, Kurz A (2010) Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. *Alzheimers Dement* **6**, 1-10 e11.

[247] Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ (2012) Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. *J Alzheimers Dis* **31**, 225-236.

[248] Valls-Pedret C, Sala-Vila A, Serra-Mir M, Corella D, de la Torre R, Martinez-Gonzalez MA, Martinez-Lapiscina EH, Fito M, Perez-Heras A, Salas-Salvado J, Estruch R, Ros E (2015) Mediterranean diet and age-related cognitive decline: a randomized clinical trial. *JAMA Intern Med* **175**, 1094-1103.

[249] Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol* **9**, 119-128.

[250] Jack CR, Jr., Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, Pankratz VS, Senjem ML, Gunter JL, Mielke MM, Lowe VJ, Boeve BF, Petersen RC (2013) Brain beta-amyloid load approaches a plateau. *Neurology* **80**, 890-896.

[251] Barberger Gateau P, Samieri C, Feart C, Plourde M (2011) Dietary omega 3 polyunsaturated fatty acids and Alzheimer’s disease: Interaction with apolipoprotein E genotype. *Curr Alzheimer Res* **8**, 479-491.

[252] Alles B, Samieri C, Feart C, Jutand M, Laurin D, Barberger-Gateau P (2012) Dietary patterns: a novel approach to examine the link between nutrition and cognitive function in older individuals. *Nutr Res Rev* **25**, 207-222.

[253] Lourida I, Soni M, Thompson-Coon J, Purandare N, Lang IA, Ukoumunne OC, Llewellyn DJ (2013) Mediterranean diet, cognitive function, and dementia: a systematic review. *Epidemiology* **24**, 479-489.

[254] Grima NA, Pase MP, Macpherson H, Pipingas A (2012) The effects of multivitamins on cognitive performance: a systematic review and meta-analysis. *J Alzheimers Dis* **29**, 561-569.

[255] Cansev M, van Wijk N, Turkyilmaz M, Orhan F, Sijben JW, Broersen LM (2015) A specific multi-nutrient enriched diet enhances hippocampal cholinergic transmission in aged rats. *Neurobiol Aging* **36**, 344-351.

[256] Wurtman RJ, Cansev M, Sakamoto T, Ulus IH (2009) Use of phosphatide precursors to promote synaptogenesis. *Annu Rev Nutr* **29**, 59-87.

[257] Li G, Millard SP, Peskind ER, Zhang J, Yu CE, Leverenz JB, Mayer C, Shofer JS, Raskind MA, Quinn JF, Galasko DR, Montine TJ (2014) Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. *JAMA Neurol* **71**, 742-751.

[258] Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P (2012) Antioxidants for Alzheimer Disease: A Randomized Clinical Trial With Cerebrospinal Fluid Biomarker Measures. *Arch Neurol* **69**, 836-841.

**FIGURE LEGENDS**

**Table 1.** Contribution of epidemiology to design more efficient RCTs assessing the impact of nutrition on cognition.

|  |  |
| --- | --- |
| What epidemiology tells us | What RCTs should do |
| Lower intake or blood levels of some nutrients are associated with higher risk of cognitive decline or dementia | =>Target individuals with specific nutritional insufficiency, based on dietary or biological data  |
| Significant cognitive decline is a late event in neurodegenerative diseases  | =>Target at risk individuals with more sensitive neuropsychological tests and biomarkers  |
| Interaction between ω-3 PUFA status and APOE4  | =>Stratify RCTs according to APOE4 genotype and probably other single nucleotides polymorphisms (SNPs) |
| Healthy diets are associated with lower risk of cognitive decline or AD  | =>Use dietary supplements providing similar combinations of nutrients  |
| AD is a multi-factorial disease whose natural history spreads over decades | => Use early and specific outcomes: -biomarkers of disease progression-biomarkers of mechanisms of action (oxidative stress, inflammation, insulin resistance, lipids… etc.) in combination with cognitive outcomes  |

**Figure 1.** Overview of links between lifestyle interventions on cognition and healthy brain function during aging.